Q4 2025 Northwest Healthcare Properties REIT Earnings Call

Speaker #2: Following the presentation, we will conduct a question-and-answer session. If at any time during this call you require immediate assistance, please press star, then zero, for an operator.

Speaker #2: This call is being recorded today, Wednesday, February 25th, 2026. I would now like to turn the conference over to Alyssa Barry, Investor Relations for Northwest.

Speaker #2: Please go ahead.

Speaker #3: Good morning, everyone, and welcome to Northwest's fourth quarter and year-end 2025 conference call. Thank you for joining us today. This call is being recorded, and a replay will be made available on our website at www.nwhireat.com.

Rachel Smith: Good morning, everyone, welcome to Northwest's Q4 and year-end 2025 Conference Call. Thank you for joining us today. This call is being recorded, a replay will be made available on our website at www.nwhreit.com. Today's discussion includes forward-looking statements. As always, we want to caution you that such statements are based on management's assumptions and beliefs. These forward-looking statements are subject to uncertainties and other factors that could cause actual results to differ materially from such statements. Please see our public filings on SEDAR+, including our MD&A and annual information form, for a discussion of these risk factors. During this call, we will also discuss non-IFRS financial measures and a reconciliation of these measures to the most directly comparable IFRS financial measures, which are available in our MD&A and earnings release.

Alyssa Barry: Good morning, everyone, welcome to Northwest's Q4 and year-end 2025 Conference Call. Thank you for joining us today. This call is being recorded, a replay will be made available on our website at www.nwhreit.com. Today's discussion includes forward-looking statements. As always, we want to caution you that such statements are based on management's assumptions and beliefs. These forward-looking statements are subject to uncertainties and other factors that could cause actual results to differ materially from such statements. Please see our public filings on SEDAR+, including our MD&A and annual information form, for a discussion of these risk factors. During this call, we will also discuss non-IFRS financial measures and a reconciliation of these measures to the most directly comparable IFRS financial measures, which are available in our MD&A and earnings release.

Speaker #3: Today's discussion includes forward-looking statements. As always, we want to caution you that such statements are based on management's assumptions and beliefs. These forward-looking statements are subject to uncertainties, and other factors that could cause actual results to differ materially from such statements.

Speaker #3: Please see our public filings on cedarplus, including our MDNA and annual information form for a discussion of these risk factors. Also, during this call, we will also discuss non-IFRS financial measures and a reconciliation of these measures to the most directly comparable IFRS financial measures which are available in our MDNA and earnings release.

Speaker #3: Please note that all currencies referenced today are in Canadian dollars unless otherwise stated. Presenting on today's call are Zach Vaughan, our CEO, and Stephanie Karamarkovic, our CFO.

Rachel Smith: Please note that all currencies referenced today are in Canadian dollars, unless otherwise stated. Presenting on today's call are Zach Vaughan, our CEO, and Stephanie Karamarkovic, our CFO. Mike Brady, our President, and Tracey Whittall, our COO, are also present and available for the question and answer session. With that, I'll now turn it over to Zach for his opening remarks.

Alyssa Barry: Please note that all currencies referenced today are in Canadian dollars, unless otherwise stated. Presenting on today's call are Zach Vaughan, our CEO, and Stephanie Karamarkovic, our CFO. Mike Brady, our President, and Tracey Whittall, our COO, are also present and available for the question and answer session. With that, I'll now turn it over to Zach for his opening remarks.

Speaker #3: Mike Brady, our President, and Tracy Whittal, our COO, are also present and available for the question-and-answer session. With that, I'll now turn it over to Zach for his opening remarks.

Speaker #4: Well, thanks, Alyssa. Good morning, everyone, and thank you for joining us on the call today as we discuss our Q4 and our 2025 results.

Zachary Vaughan: Well, thanks, Alyssa. Good morning, everyone, and thank you for joining us on the call today as we discuss our Q4 and our 2025 results. It's been a very busy quarter and a busy year for our business. During 2025, we've been focused on 4 key areas. 1, performance in our existing portfolio. 2, our balance sheet and liquidity. 3, simplifying our business. 4, future growth. I'm happy to say that with what we accomplished in Q4 and throughout 2025, we've advanced progress across all these 4 key areas. Starting with performance in our portfolio. Operationally, our portfolio did what it should. It delivered stable and growing cash flows. Stephanie's gonna touch more on the specific details in a second, but overall, the results were strong.

Zachary Vaughan: Well, thanks, Alyssa. Good morning, everyone, and thank you for joining us on the call today as we discuss our Q4 and our 2025 results. It's been a very busy quarter and a busy year for our business. During 2025, we've been focused on 4 key areas. 1, performance in our existing portfolio. 2, our balance sheet and liquidity. 3, simplifying our business. 4, future growth. I'm happy to say that with what we accomplished in Q4 and throughout 2025, we've advanced progress across all these 4 key areas. Starting with performance in our portfolio. Operationally, our portfolio did what it should. It delivered stable and growing cash flows. Stephanie's gonna touch more on the specific details in a second, but overall, the results were strong.

Speaker #4: It's been a very busy quarter, and a busy year, for our business. During 2025, we've been focused on four key areas: one, performance in our existing portfolio; two, our balance sheet and liquidity; three, simplifying our business; and four, future growth.

Speaker #4: And I'm happy to say that with what we accomplished in Q4 and throughout 2025, we've advanced progress across all these four key areas. Starting with performance in our portfolio, operationally, our portfolio did what it should.

Speaker #4: It delivered stable and growing cash flows. Stephanie's going to touch more on the specific details in a second, but overall, the results were strong.

Speaker #4: Same property NOI for the year grew by over 3% with positive contributions from all regions. And we finished 2025 with an occupancy of over 96% and a weighted average lease term of over 12 years.

Zachary Vaughan: Same-property NOI for the year grew by over 3%, with positive contributions from all regions. We finished 2025 with an occupancy of over 96% and a weighted average lease term of over 12 years. Our AFFO per unit increased about 9% this year. Our payout ratio has come down to around 85% for 2025. Turning to the balance sheet and liquidity, during 2025, we executed over $0.5 billion of asset sales across three regions, including fully exiting the UK and completing the internalization of Vital in New Zealand. The proceeds were used primarily to deleverage. During 2025, our proportionate leverage fell by about 600 basis points. Our weighted average interest rate fell by about 80 basis points, which is materially improving our cost of capital.

Zachary Vaughan: Same-property NOI for the year grew by over 3%, with positive contributions from all regions. We finished 2025 with an occupancy of over 96% and a weighted average lease term of over 12 years. Our AFFO per unit increased about 9% this year. Our payout ratio has come down to around 85% for 2025. Turning to the balance sheet and liquidity, during 2025, we executed over $0.5 billion of asset sales across three regions, including fully exiting the UK and completing the internalization of Vital in New Zealand. The proceeds were used primarily to deleverage. During 2025, our proportionate leverage fell by about 600 basis points. Our weighted average interest rate fell by about 80 basis points, which is materially improving our cost of capital.

Speaker #4: Our AFFO per unit increased about 9% this year, and our payout ratio has come down to around 85% for 2025. Turning to the balance sheet and liquidity, during 2025, we executed over half a billion dollars of asset sales across three regions, including fully exiting the UK and completing the internalization of Vital.

Speaker #4: In New Zealand, the proceeds were used primarily to deleverage during 2025. Our proportionate leverage fell by about 600 basis points. And our weighted average interest rate fell by about 80 basis points, which is materially improving our cost of capital.

Speaker #4: We also suspended our DRIP and put in place an NCIB. And as it relates to liquidity, at the end of the year, our available liquidity is over 450 million dollars, which is a terrific position that gives us a lot of flexibility going forward.

Zachary Vaughan: We also suspended our DRIP and put in place an NCIB. As it relates to liquidity, at the end of the year, our available liquidity is over $450 million, which is a terrific position that gives us a lot of flexibility going forward. In terms of simplification, this is critical to our future success. You know, I've seen through my career that complexity rarely pays off and simplicity sells, particularly as it relates to real estate. Our plan over time is to focus on our home markets. This year, we made some progress towards this goal.

Zachary Vaughan: We also suspended our DRIP and put in place an NCIB. As it relates to liquidity, at the end of the year, our available liquidity is over $450 million, which is a terrific position that gives us a lot of flexibility going forward. In terms of simplification, this is critical to our future success. You know, I've seen through my career that complexity rarely pays off and simplicity sells, particularly as it relates to real estate. Our plan over time is to focus on our home markets. This year, we made some progress towards this goal.

Speaker #4: In critical to our future success. I've seen through my career that complexity rarely pays off, and simplicity sells, particularly as it relates to real estate.

Speaker #4: And our plan over time is to focus on our home markets. And this year, we made some progress towards this goal. We fully exited the UK.

Zachary Vaughan: We fully exited the UK, we streamlined Australia and New Zealand, after the year-end, we reached an agreement to sell a substantial portion of our holdings in Europe in a EUR 400 million transaction, advancing our goals to eventually exit the region. These steps, taken together, are gonna help shrink our footprint, which is gonna reduce complexity and costs over time, and also free up capital to recycle back here. In terms of growth, given all the work the teams put in, this year and last year, we're now fortunately in a position to start looking ahead. You know, something surprising I learned was that it's been about 8 years since the REIT has completed an acquisition here in Canada, our home market. That ended in Q4, where we committed to acquire a 157-bed transitional care facility in Ottawa.

Zachary Vaughan: We fully exited the UK, we streamlined Australia and New Zealand, after the year-end, we reached an agreement to sell a substantial portion of our holdings in Europe in a EUR 400 million transaction, advancing our goals to eventually exit the region. These steps, taken together, are gonna help shrink our footprint, which is gonna reduce complexity and costs over time, and also free up capital to recycle back here. In terms of growth, given all the work the teams put in, this year and last year, we're now fortunately in a position to start looking ahead. You know, something surprising I learned was that it's been about 8 years since the REIT has completed an acquisition here in Canada, our home market. That ended in Q4, where we committed to acquire a 157-bed transitional care facility in Ottawa.

Speaker #4: We streamlined Australia and New Zealand. And after the year-end, we reached an agreement to sell a substantial portion of our holdings in Europe in a €400 million transaction, advancing our goals to eventually exit the region.

Speaker #4: Now, these steps taken together are going to help shrink our footprint, which is going to reduce complexity and costs over time, and also free up capital to recycle back here.

Speaker #4: In terms of growth, given all the work the team's put in this year and last year, we're now fortunately in a position to start looking ahead.

Speaker #4: Something surprising I learned was that it's been about eight years since the REIT has completed an acquisition here in Canada, our home market. But that ended in Q4, where we committed to acquire 157-bed transitional care facility in Ottawa.

Speaker #4: The assets adjacent to the Ottawa hospitals' main campus and is leased by them on a long-term basis. In addition to this asset being a key piece of the hospital's healthcare delivery plan, this investment should lead to further opportunities to partner with them as they continue to grow.

Zachary Vaughan: The asset's adjacent to The Ottawa Hospital's main campus and is leased by them on a long-term basis. This asset being a key piece of the hospital's healthcare delivery plan, this investment should lead to further opportunities to partner with them as they continue to grow. In addition to acquisitions, we plan to be the partner of choice in Canada as hospitals and health systems increase the type of procedures and care that they provide in outpatient settings. The positive results of this shift are demonstrated by the success of the ambulatory surgery center we delivered about 24 months ago in partnership with Lakeridge Health. Since opening, that facility has supported about 20,000 surgeries to improve the hospital's productivity and helping, which helps to reduce the wait times.

Zachary Vaughan: The asset's adjacent to The Ottawa Hospital's main campus and is leased by them on a long-term basis. This asset being a key piece of the hospital's healthcare delivery plan, this investment should lead to further opportunities to partner with them as they continue to grow. In addition to acquisitions, we plan to be the partner of choice in Canada as hospitals and health systems increase the type of procedures and care that they provide in outpatient settings. The positive results of this shift are demonstrated by the success of the ambulatory surgery center we delivered about 24 months ago in partnership with Lakeridge Health. Since opening, that facility has supported about 20,000 surgeries to improve the hospital's productivity and helping, which helps to reduce the wait times.

Speaker #4: And in addition to acquisitions, we plan to be the partner of choice in Canada, as hospitals and health systems increase the type of procedures and care that they provide in outpatient settings.

Speaker #4: The positive results of this shift are demonstrated by the success of the ambulatory surgery center we delivered about 24 months ago in partnership with Lakewood Hospital.

Speaker #4: Now, since opening that facility, it has supported about 20,000 surgeries. It's improved the hospital's productivity in helping which helps to reduce their wait times.

Speaker #4: And I'm very excited to announce that in the fourth quarter, we signed a binding commitment to build 120,000 square foot health services building for a large Canadian hospital.

Zachary Vaughan: I'm very excited to announce that in Q4, we signed a binding commitment to build a 120,000 sq ft health services building for a large Canadian hospital. When this asset is completed in 2029, the hospital's gonna occupy it on a long-term basis and use it to move non-critical procedures out of their main facility. This transaction and our experience with Lakeridge really demonstrates that we can deliver assets that not only benefit Canada's healthcare system but also add long-term infrastructure-like investments to our portfolio. We're very excited about this opportunity and also about the opportunities like this that we expect going forward, which we think will be a major avenue of future growth for us. Given all the changes happening and the new direction we're taking at the REIT, our board's approved a name change.

Zachary Vaughan: I'm very excited to announce that in Q4, we signed a binding commitment to build a 120,000 sq ft health services building for a large Canadian hospital. When this asset is completed in 2029, the hospital's gonna occupy it on a long-term basis and use it to move non-critical procedures out of their main facility. This transaction and our experience with Lakeridge really demonstrates that we can deliver assets that not only benefit Canada's healthcare system but also add long-term infrastructure-like investments to our portfolio. We're very excited about this opportunity and also about the opportunities like this that we expect going forward, which we think will be a major avenue of future growth for us. Given all the changes happening and the new direction we're taking at the REIT, our board's approved a name change.

Speaker #4: When this asset is completed in 2029, the hospital's going to occupy it on a long-term basis, and use it to move non-critical procedures out of their main facility.

Speaker #4: Now, this transaction in our experience with Lakewood really demonstrates that we can deliver assets that not only benefit Canada's healthcare system, but also add long-term infrastructure-like investments to our portfolio.

Speaker #4: So we're very excited about this opportunity and also about the opportunities like this that we expect going forward, which we think will be a major avenue of future growth for us.

Speaker #4: Given all the changes happening and the new direction we're taking at the REIT, our board's approved a name change. In the next few weeks, our name is going to change from Northwest Healthcare Properties REIT to Vital Infrastructure Property Trust.

Zachary Vaughan: In the next few weeks, our name is gonna change from Northwest Healthcare Properties REIT to Vital Infrastructure Property Trust. Our new tickers and website will become effective. Although our name's changing and our geographic exposure is going to trend towards the Americas over time, our focus remains the same. We're going to invest in and manage high quality, hard to replicate healthcare infrastructure, supported by strong underlying credit to generate reliable and secure cash flows for our unitholders. Now, before handing it over to Stephanie, I'll say a few things about Healthscope, given some of the noise in the Australian press recently. You know, throughout the receivership process, our teams worked to identify a new operator for our 12 hospitals.

Zachary Vaughan: In the next few weeks, our name is gonna change from Northwest Healthcare Properties REIT to Vital Infrastructure Property Trust. Our new tickers and website will become effective. Although our name's changing and our geographic exposure is going to trend towards the Americas over time, our focus remains the same. We're going to invest in and manage high quality, hard to replicate healthcare infrastructure, supported by strong underlying credit to generate reliable and secure cash flows for our unitholders. Now, before handing it over to Stephanie, I'll say a few things about Healthscope, given some of the noise in the Australian press recently. You know, throughout the receivership process, our teams worked to identify a new operator for our 12 hospitals.

Speaker #4: And our new tickers and website will become effective. Although our name's changing and our geographic exposure is going to trend towards the Americas over time, our focus remains the same.

Speaker #4: We're going to invest in and manage high-quality, hard-to-replicate healthcare infrastructure supported by strong underlying credit to generate reliable, secure cash flows for our unit holders.

Speaker #4: Now, before handing it over to Stephanie, I'll say a few things about Healthscope. Given some of the noise in the Australian press recently, throughout the receivership process, our teams worked to identify a new operator for our 12 hospitals.

Speaker #4: In November, we, with the full support of and encouragement of the receivers, entered into a transaction with a group with a group called Cavalry Healthcare.

Zachary Vaughan: In November, we, with the full support of and encouragement of the receivers, entered into a transaction with a group, with a group called Calvary Health Care. Now, they're a large, not-for-profit operator of hospitals and senior care facilities. It's highly regarded throughout Australia. Based on the terms that we agreed with them, the initial financial impact to us was very minimal. Importantly, our deal included an opportunity for us to potentially participate in outer year profitability of the hospitals, which continues to improve today and certainly would continue to do so under their control. We were very surprised when we heard from the receivers that this proposal was not yet accepted, and that they were planning to convert Healthscope to a not-for-profit entity.

Zachary Vaughan: In November, we, with the full support of and encouragement of the receivers, entered into a transaction with a group, with a group called Calvary Health Care. Now, they're a large, not-for-profit operator of hospitals and senior care facilities. It's highly regarded throughout Australia. Based on the terms that we agreed with them, the initial financial impact to us was very minimal. Importantly, our deal included an opportunity for us to potentially participate in outer year profitability of the hospitals, which continues to improve today and certainly would continue to do so under their control. We were very surprised when we heard from the receivers that this proposal was not yet accepted, and that they were planning to convert Healthscope to a not-for-profit entity.

Speaker #4: Now, they're a large, not-for-profit operator of hospitals and senior care facilities. It's highly regarded throughout Australia. Based on the terms that we agreed with them, the initial financial impact to us was very minimal.

Speaker #4: But importantly, our deal included an opportunity for us to potentially participate in out-of-year profitability of the hospitals, which continues to improve today, and certainly would continue to do so under their control.

Speaker #4: So we're very surprised when we heard from the receivers that this proposal was not yet accepted. And that they were planning to convert Healthscope to a not-for-profit entity.

Speaker #4: Now, there are benefits to a not-for-profit entity, including operating savings that the receivers indicated are over $100 million a year, which is their landlord is a great thing for us.

Zachary Vaughan: Now, there are benefits to a not-for-profit entity, including operating savings, that the receivers indicated are over CAD 100 million a year, which as their landlord, is a great thing for us. Beyond this, we don't know anything about their plans. We've asked the receiver some very basic information, but have yet to receive a response from them. We still believe there are meaningful benefits to all the parties from having the deal we had with Calvary Health Care in place. At this point, Healthscope remains our tenant. They continue to pay their rent, so we have no mechanism to accelerate a transition at this time, although we do remain highly supportive of it. We do hope that there's a resolution to this issue in the near term.

Zachary Vaughan: Now, there are benefits to a not-for-profit entity, including operating savings, that the receivers indicated are over CAD 100 million a year, which as their landlord, is a great thing for us. Beyond this, we don't know anything about their plans. We've asked the receiver some very basic information, but have yet to receive a response from them. We still believe there are meaningful benefits to all the parties from having the deal we had with Calvary Health Care in place. At this point, Healthscope remains our tenant. They continue to pay their rent, so we have no mechanism to accelerate a transition at this time, although we do remain highly supportive of it. We do hope that there's a resolution to this issue in the near term.

Speaker #4: But beyond this, we don't know anything about their plans. We've asked the receivers some very basic information, but have yet to receive a response from them.

Speaker #4: We still believe they're meaningful benefits to all the parties from having the deal we had with Cavalry in place. But at this point, Healthscope remains our tenant.

Speaker #4: They continue to pay their rent. So we have no mechanism to accelerate a transition at this time, although we do remain highly supportive of it.

Speaker #4: We do hope that there's a resolution to this issue in the near term. I can assure you that Stephanie and I would be thrilled to not have to respond to every Australian press article, or spend time talking about Healthscope on all of our quarterly calls with all of you.

Zachary Vaughan: I can assure you that Stephanie and I'd be thrilled to not have to respond to every Australian press article, or spend time talking about Healthscope on all of our quarterly calls with all of you. Just to close out, Q4 and 2025 were very busy and productive. Our assets performed well, our balance sheet and liquidity are stronger, the business is getting simpler, and we're finding new avenues of growth. I'm very encouraged by the progress that we've made to date, and I'm confident in the path ahead. I want to thank our team and all our unitholders for their support, as we execute on this next phase of our business under the new banner of Vital Infrastructure. With that, I'll hand it to Stephanie.

Zachary Vaughan: I can assure you that Stephanie and I'd be thrilled to not have to respond to every Australian press article, or spend time talking about Healthscope on all of our quarterly calls with all of you. Just to close out, Q4 and 2025 were very busy and productive. Our assets performed well, our balance sheet and liquidity are stronger, the business is getting simpler, and we're finding new avenues of growth. I'm very encouraged by the progress that we've made to date, and I'm confident in the path ahead. I want to thank our team and all our unitholders for their support, as we execute on this next phase of our business under the new banner of Vital Infrastructure. With that, I'll hand it to Stephanie.

Speaker #4: Just to close out, the fourth quarter in 2025—we’re very busy and productive. Our assets perform well. Our balance sheet and liquidity are stronger.

Speaker #4: The business is getting simpler. And we're finding new avenues of growth. I'm very encouraged by the progress that we've made to date. I'm confident in the path ahead.

Speaker #4: I want to thank our team and all our unit holders for their support as we execute on this next phase of our business under the new banner of Vital Infrastructure.

Speaker #4: With that, I'll hand it to Stephanie.

Speaker #5: Thanks, Zach. And good morning, everyone. Before I begin, I want to highlight the reporting changes following the internalization of Vital Trust Management Structure, which closed on December 30th, 2025.

Stephanie Karamarkovic: Thanks, Zach. Good morning, everyone. Before I begin, I want to highlight the reporting changes following the internalization of Vital Trust management structure, which closed on 30 December 2025. As a result, the REIT no longer controls Vital Trust, and its results were deconsolidated effective that date. Accordingly, 2025 results are not directly comparable to prior periods. Our retained interest in Vital Trust is now accounted for as an equity investment under IFRS, and presented as a standalone investment on a proportionate basis. As the transaction closed on 30 December, there was no impact on proportionate earnings for 2025. Vital Trust's operating results have also been removed from our leasing metrics and portfolio profile as at year-end. Beginning in Q1, the REIT's proportionate results will reflect distribution income received from Vital Trust.

Stephanie Karamarkovic: Thanks, Zach. Good morning, everyone. Before I begin, I want to highlight the reporting changes following the internalization of Vital Trust management structure, which closed on 30 December 2025. As a result, the REIT no longer controls Vital Trust, and its results were deconsolidated effective that date. Accordingly, 2025 results are not directly comparable to prior periods. Our retained interest in Vital Trust is now accounted for as an equity investment under IFRS, and presented as a standalone investment on a proportionate basis. As the transaction closed on 30 December, there was no impact on proportionate earnings for 2025. Vital Trust's operating results have also been removed from our leasing metrics and portfolio profile as at year-end. Beginning in Q1, the REIT's proportionate results will reflect distribution income received from Vital Trust.

Speaker #5: As a result, the REIT no longer controls Vital Trust and its results were deconsolidated effective that date. Accordingly, 2025 results are not directly comparable to prior periods.

Speaker #5: Our retained interest in Vital Trust is now accounted for as an equity investment under IFRS and presented as a standalone investment on a proportionate basis.

Speaker #5: As the transaction closed on December 30th, there was no impact on proportionate earnings for 2025. Vital Trust's operating results have also been removed from our leasing metrics and portfolio profile as of year-end.

Speaker #5: Beginning in the first quarter, the REIT's proportionate results will reflect distribution income received from Vital Trust. Q4 marked another quarter of solid financial and operating performance.

Stephanie Karamarkovic: Q4 marked another quarter of solid financial and operating performance. We enter 2026 well positioned to execute on a refreshed strategy under our new identity and drive unitholder value. Today, I will review our operating and financial results for the quarter and full year, discuss the balance sheet transformation completed in 2025, and provide an update on transactional activity and what it means for 2026 and beyond. First, I will review the REIT's key operating and financial results. During Q4 and throughout 2025, the portfolio delivered strong operational performance, reinforcing both our execution and asset quality. Same Property Net Operating Income increased 3% in the quarter and 3.1% for the year, driven by inflationary, indexed, and contractual rent increases, as well as rentalized capital expenditures.

Stephanie Karamarkovic: Q4 marked another quarter of solid financial and operating performance. We enter 2026 well positioned to execute on a refreshed strategy under our new identity and drive unitholder value. Today, I will review our operating and financial results for the quarter and full year, discuss the balance sheet transformation completed in 2025, and provide an update on transactional activity and what it means for 2026 and beyond. First, I will review the REIT's key operating and financial results. During Q4 and throughout 2025, the portfolio delivered strong operational performance, reinforcing both our execution and asset quality. Same Property Net Operating Income increased 3% in the quarter and 3.1% for the year, driven by inflationary, indexed, and contractual rent increases, as well as rentalized capital expenditures.

Speaker #5: And we enter 2026 well-positioned to execute on a refresh strategy under our new identity and drive unit holder value. Today, I will review our operating and financial results for the quarter and full year, discuss the balance sheet transformation completed in 2025, and provide an update on transactional activity and what it means for 2026 and beyond.

Speaker #5: First, I will review the REIT's key operating and financial results. During Q4 and throughout 2025, the portfolio delivered strong operational performance, reinforcing both our execution and asset quality.

Speaker #5: Same property net operating income increased 3% in the quarter and 3.1% for the year, driven by inflationary index and contractual rent increases, as well as rentalized capital expenditures.

Speaker #5: In Q4, we completed $287,000 square feet of leasing at an retention rate. For the full year, we renewed secured or secured $1.1 million square feet of leases, including over 200,000 feet of early lease extensions, with an 88% retention.

Stephanie Karamarkovic: In Q4, we completed 287,000 sq ft of leasing at an activity at an 85% retention rate. For the full year, we renewed, secured, or secured 1.1 million sq ft of leases, including over 200,000 ft of early lease extensions, with an 88% retention. Year-end occupancy was 96.4%, which is consistent year-over-year, and our weighted average lease expiry remains over 12 years, demonstrating the predictable and long-dated nature of our cash flows. Turning to G&A, excluding unit-based compensation and severance, Q4 expenses increased by CAD 0.8 million year-over-year, largely due to timing and lower salary capitalization. On the same adjusted basis, full year G&A declined by CAD 1.5 million in 2025, as we continue to simplify the business and reduce headcount, partially offset by FX.

Stephanie Karamarkovic: In Q4, we completed 287,000 sq ft of leasing at an activity at an 85% retention rate. For the full year, we renewed, secured, or secured 1.1 million sq ft of leases, including over 200,000 ft of early lease extensions, with an 88% retention. Year-end occupancy was 96.4%, which is consistent year-over-year, and our weighted average lease expiry remains over 12 years, demonstrating the predictable and long-dated nature of our cash flows. Turning to G&A, excluding unit-based compensation and severance, Q4 expenses increased by CAD 0.8 million year-over-year, largely due to timing and lower salary capitalization. On the same adjusted basis, full year G&A declined by CAD 1.5 million in 2025, as we continue to simplify the business and reduce headcount, partially offset by FX.

Speaker #5: Year-end occupancy was 96.4%, which is consistent year over year, and our weighted average lease expiry remains over 12 years, demonstrating the predictable and long-dated nature of our cash flows.

Speaker #5: Turning to G&A and excluding unit-based compensation and severance, Q4 expenses increased by 0.8 million year over year, largely due to timing and lower salary capitalization.

Speaker #5: On the same adjusted basis, full-year G&A declined by 1.5 million in 2025, as we continue to simplify the business and reduce headcount, partially offset by FX.

Speaker #5: Looking ahead, we expect further G&A reductions throughout 2026, following the Vital internalization and the sale of a significant portion of our European business. AFFO per unit was $0.12 in Q4 and $0.42 for the full year, representing increases of 20% and 8%, respectively.

Stephanie Karamarkovic: Looking ahead, we expect further G&A reductions throughout 2026, following the Vital internalization and the sale of a significant portion of our European business. AFFO per unit was $0.12 in Q4 and $0.42 for the full year, representing increases of 20% and 8% respectively. The full year payout ratio improved to 86%, down from 92% in 2024, and now comfortably within our stated target range. Growth in AFFO year-over-year was driven primarily by lower interest expenses and current taxes, partially offset by reduced NOI from non-core asset sales and lower management fees. NAV per unit was $7.55, down $1 from last December. The decline primarily reflects the Vital internalization, including the revaluation of the global manager, dilution from Vital's equity raise, and the updated fair value presentation of our retained interest.

Stephanie Karamarkovic: Looking ahead, we expect further G&A reductions throughout 2026, following the Vital internalization and the sale of a significant portion of our European business. AFFO per unit was $0.12 in Q4 and $0.42 for the full year, representing increases of 20% and 8% respectively. The full year payout ratio improved to 86%, down from 92% in 2024, and now comfortably within our stated target range. Growth in AFFO year-over-year was driven primarily by lower interest expenses and current taxes, partially offset by reduced NOI from non-core asset sales and lower management fees. NAV per unit was $7.55, down $1 from last December. The decline primarily reflects the Vital internalization, including the revaluation of the global manager, dilution from Vital's equity raise, and the updated fair value presentation of our retained interest.

Speaker #5: The full-year payout ratio improved to 86%, down from 92% in 2024, and now comfortably within our stated target range. Growth in AFFO year over year was driven primarily by lower interest expenses and current taxes, partially offset by reduced NOI from non-core asset sales and lower management fees.

Speaker #5: NAV per unit was 755, down $1 from last December. The decline primarily reflects the Vital internalization, including the revaluation of the global manager, dilution from Vital's equity raise, and the updated fair value presentation of our retained interest.

Speaker #5: NAV was also impacted by the fair value changes across the portfolio, including assets classified as held for sale in Europe. Moving to transactional activity, Q4 and early 2026 have been highly active periods for the REIT, as we continued executing on our strategy to simplify the business and reduce leverage.

Stephanie Karamarkovic: NAV was also impacted by the fair value changes across the portfolio, including assets classified as held for sale in Europe. Moving to transactional activity. Q4 and early 2026 have been highly active periods for the REIT, as we continued executing on our strategy to simplify the business and reduce leverage. Importantly, we are now demonstrating our ability to redeploy capital into North America, where we are achieving stronger returns with lower frictional costs and reduced complexity. During the quarter, we sold one Canadian property and two assets within Vital Trust at IFRS book values, generating total proceeds of CAD 80 million. We also completed the previously announced Vital Trust internalization on 30 December and used proceeds to pay approximately CAD 127 million of debt before year-end and a further CAD 24 million in January and February of this year.

Stephanie Karamarkovic: NAV was also impacted by the fair value changes across the portfolio, including assets classified as held for sale in Europe. Moving to transactional activity. Q4 and early 2026 have been highly active periods for the REIT, as we continued executing on our strategy to simplify the business and reduce leverage. Importantly, we are now demonstrating our ability to redeploy capital into North America, where we are achieving stronger returns with lower frictional costs and reduced complexity. During the quarter, we sold one Canadian property and two assets within Vital Trust at IFRS book values, generating total proceeds of CAD 80 million. We also completed the previously announced Vital Trust internalization on 30 December and used proceeds to pay approximately CAD 127 million of debt before year-end and a further CAD 24 million in January and February of this year.

Speaker #5: Importantly, we are now demonstrating our ability to redeploy capital into North America where we are achieving stronger returns with lower frictional costs and reduced complexity.

Speaker #5: During the quarter, we sold one Canadian property and two assets within Vital Trust at IFRS book values, generating total proceeds of 80 million. We also completed the previously announced Vital Trust internalization on December 30th and used proceeds to pay approximately $127 million of debt before year-end and a further $24 million in January and February of this year.

Speaker #5: The transaction strengthens the balance sheet on an AFFO neutral basis and simplifies our structure in Australasia, while providing flexibility to further reduce our exposure to New Zealand over time.

Stephanie Karamarkovic: The transaction strengthens the balance sheet on an AFFO neutral basis and simplifies our structure in Australasia, while providing flexibility to further reduce our exposure to New Zealand over time. In Europe, following a broad marketing process involving multiple credible bidders, we finalized an agreement yesterday to sell 33 properties for gross pre-proceeds of EUR 400 million, or approximately CAD 650 million, before adjustments to TPG Real Estate. We expect this transaction to be earnings neutral after debt repayment and platform cost reductions. Closing is expected by the end of Q2, with estimated net proceeds of approximately CAD 145 million at the REIT's proportionate share to further delever and support capital redeployment.

Stephanie Karamarkovic: The transaction strengthens the balance sheet on an AFFO neutral basis and simplifies our structure in Australasia, while providing flexibility to further reduce our exposure to New Zealand over time. In Europe, following a broad marketing process involving multiple credible bidders, we finalized an agreement yesterday to sell 33 properties for gross pre-proceeds of EUR 400 million, or approximately CAD 650 million, before adjustments to TPG Real Estate. We expect this transaction to be earnings neutral after debt repayment and platform cost reductions. Closing is expected by the end of Q2, with estimated net proceeds of approximately CAD 145 million at the REIT's proportionate share to further delever and support capital redeployment.

Speaker #5: In Europe, following a broad marketing process involving multiple credible bidders, we finalized an agreement yesterday to sell 33 properties for gross proceeds of $400 million or approximately $650 million Canadian before adjustments to TPG real estate.

Speaker #5: We expect this transaction to be earnings neutral after debt repayment and platform cost reductions. Closing is expected by the end of Q2, with estimated net proceeds of approximately $145 million at the REIT's proportionate share to further delever and support capital redeployment.

Speaker #5: On the growth front, in Q4, we signed a $112 million build-to-suit development agreement with a Canadian hospital system, with construction to begin in late 2026.

Stephanie Karamarkovic: On the growth front, in Q4, we signed a $112 million build-to-suit development agreement with a Canadian hospital system, with construction to begin in late 2026. This marks our second major healthcare development in Canada, following the successful completion of Lakeridge, the Lakeridge project in 2024, and we believe similar opportunities will continue to emerge as healthcare delivery increasingly shifts towards non-acute settings. In February, we agreed to acquire a 73,000 sq ft transitional care facility in Ottawa for $49 million. The property is leased to The Ottawa Hospital, with over 14 years remaining and annual rent escalations. The transaction is expected to close in early March and will be funded from existing liquidity. I'd like to highlight the progress made in the last year in improving the balance sheet and in reducing our cost of debt.

Stephanie Karamarkovic: On the growth front, in Q4, we signed a $112 million build-to-suit development agreement with a Canadian hospital system, with construction to begin in late 2026. This marks our second major healthcare development in Canada, following the successful completion of Lakeridge, the Lakeridge project in 2024, and we believe similar opportunities will continue to emerge as healthcare delivery increasingly shifts towards non-acute settings. In February, we agreed to acquire a 73,000 sq ft transitional care facility in Ottawa for $49 million. The property is leased to The Ottawa Hospital, with over 14 years remaining and annual rent escalations. The transaction is expected to close in early March and will be funded from existing liquidity. I'd like to highlight the progress made in the last year in improving the balance sheet and in reducing our cost of debt.

Speaker #5: This marks our second major healthcare development in Canada, following the successful completion of Lakeridge Project in 2024, and we believe similar opportunities will continue to emerge as healthcare delivery increasingly shifts towards non-acute settings.

Speaker #5: In addition, in February, we agreed to acquire a 73,000 square foot transitional care facility in Ottawa for $49 million. The property is leased to The Ottawa Hospital with over 14 years remaining and annual rent escalations.

Speaker #5: The transaction is expected to close in early March and will be funded from existing liquidity. Lastly, I'd like to highlight the progress made in the last year in improving the balance sheet and in reducing our cost of debt.

Speaker #5: In 2025, through our disposition activities, proportionate leverage declined by about $600 basis points to 52.4%, and our economic average weighted average interest rate declined by 78 basis points to 4.71%.

Stephanie Karamarkovic: In 2025, through our disposition activities, proportionate leverage declined by about 600 basis points to 52.4%, and our economic average, weighted average interest rate declined by 78 basis points to 4.71%. As of 31 December, over 90% of our debt is fixed, and our weighted average term to maturity is 2.5 years. Our debt to adjusted EBITDA ratio sits at 8.7x, adjusted to reflect the impact of the Vital internalization, which is down from 8.9x at 31 December 2024. Most importantly, our liquidity on a proportionate basis at the end of this year is CAD 465.5 million, up CAD 324 million from this time last year.

Stephanie Karamarkovic: In 2025, through our disposition activities, proportionate leverage declined by about 600 basis points to 52.4%, and our economic average, weighted average interest rate declined by 78 basis points to 4.71%. As of 31 December, over 90% of our debt is fixed, and our weighted average term to maturity is 2.5 years. Our debt to adjusted EBITDA ratio sits at 8.7x, adjusted to reflect the impact of the Vital internalization, which is down from 8.9x at 31 December 2024. Most importantly, our liquidity on a proportionate basis at the end of this year is CAD 465.5 million, up CAD 324 million from this time last year.

Speaker #5: As of December 31st, over 90% of our debt is fixed, and our weighted average term to maturity is 2.5 years. Our debt-to-adjusted EBITDA ratio sits at 8.7 times, adjusted to reflect the impact of the Vital internalization, which is down from 8.9 times at December 31st, 2024.

Speaker #5: Most importantly, our liquidity on a proportionate basis at the end of this year is $465.5 million, up $324 million from this time last year.

Speaker #5: With the majority of our deleveraging now complete, we believe the balance sheet is well-positioned to support this next phase of growth for the REIT.

Stephanie Karamarkovic: With the majority of our deleveraging now complete, we believe the balance sheet is well positioned to support this next phase of growth for the REIT. In terms of one-time updates, further to Zach's comments on Healthscope, I can confirm that Healthscope remains current on rent and continues to meet all lease obligations as they work through the sale or repositioning of their business. Throughout this process, our focus has been on preserving value and minimizing impact to earnings. While we have agreed conditional terms with a potential new operator, there are no assurances that the Calvary bid will proceed. Given the commercially sensitive nature of these discussions, we're not in a position to provide additional details at this time. With respect to Healthscope's proposal to convert to a not-for-profit structure, we have not been provided with sufficient information to assess the implications for the REIT.

Stephanie Karamarkovic: With the majority of our deleveraging now complete, we believe the balance sheet is well positioned to support this next phase of growth for the REIT. In terms of one-time updates, further to Zach's comments on Healthscope, I can confirm that Healthscope remains current on rent and continues to meet all lease obligations as they work through the sale or repositioning of their business. Throughout this process, our focus has been on preserving value and minimizing impact to earnings. While we have agreed conditional terms with a potential new operator, there are no assurances that the Calvary bid will proceed. Given the commercially sensitive nature of these discussions, we're not in a position to provide additional details at this time. With respect to Healthscope's proposal to convert to a not-for-profit structure, we have not been provided with sufficient information to assess the implications for the REIT.

Speaker #5: In terms of one-time updates, further disaster comments on Healthscope, I can confirm that Healthscope remains current on rent and continues to meet all lease obligations as they work through the sale or repositioning of their business.

Speaker #5: Throughout this process, our focus has been on preserving value and minimizing impact to earnings. While we have agreed conditional terms with a potential new operator, there are no assurances that the Calvary bid will proceed.

Speaker #5: Given the commercially sensitive nature of these discussions, we're not in a position to provide additional details at this time. And with respect to Healthscope's proposal to convert to a not-for-profit structure, we have been not provided with sufficient information to assess the implications for the REIT.

Speaker #5: In closing, 2025 is a transformative year for the REIT. We've simplified the platform, strengthened the balance sheet, and enhanced financial flexibility. With strong occupancy long lease terms and improving AFFO coverage and disciplined substantial liquidity, we enter 2026 from a position of strength.

Stephanie Karamarkovic: In closing, 2025 was a transformative year for the REIT. We've simplified the platform, strengthened the balance sheet, and enhanced financial flexibility. With strong occupancy, long lease terms, improving AFFO coverage, and disciplined substantial liquidity, we enter 2026 from a position of strength. We remain disciplined in our capital allocation and believe the work completed over the past year positions us well for the next phase of sustainable growth and value creation for unitholders. I will now turn the call back over to the operator.

Stephanie Karamarkovic: In closing, 2025 was a transformative year for the REIT. We've simplified the platform, strengthened the balance sheet, and enhanced financial flexibility. With strong occupancy, long lease terms, improving AFFO coverage, and disciplined substantial liquidity, we enter 2026 from a position of strength. We remain disciplined in our capital allocation and believe the work completed over the past year positions us well for the next phase of sustainable growth and value creation for unitholders. I will now turn the call back over to the operator.

Speaker #5: We remain disciplined in our capital allocation and believe the work completed over the past year positions us well for the next phase of sustainable growth and value creation for unit holders.

Speaker #5: I will now turn the call back over to the operator.

Speaker #1: Thank you. We'll now begin the question-and-answer session. To join the question queue, you may press star then one on your telephone keypad. You'll hear a tone acknowledging your request.

Operator: Thank you. We'll now begin the question and answer session. To join the question queue, you may press star, then one on your telephone keypad. You'll hear a tone acknowledging your request. If you're using a speakerphone, please pick up your handset before pressing any keys. To withdraw your question, please press star then two. Our first question is from Sairam Srinivas with ATB. Please go ahead.

Operator: Thank you. We'll now begin the question and answer session. To join the question queue, you may press star, then one on your telephone keypad. You'll hear a tone acknowledging your request. If you're using a speakerphone, please pick up your handset before pressing any keys. To withdraw your question, please press star then two. Our first question is from Sairam Srinivas with ATB. Please go ahead.

Speaker #1: If you're using a speakerphone, please pick up your handset before pressing any keys. To withdraw your question, please press star then two. Our first question is from Syram Srinivas with ATB.

Speaker #1: Please go ahead.

Speaker #6: Thank you, Arvinda. Good morning, everybody. Congratulations on a good quarter and a pretty active one at that. Going back to a comment on potentially exiting Europe entirely, is there something which you could probably expect in 2026?

Sairam Srinivas [Director of Research: Thank you, operator. Good morning, everybody. Congratulations on a good quarter and a pretty active one at that. Zach, going back to your comment on potentially exiting Europe entirely, is this something which you could probably expect in 2026? Can you just speak about the broader disposition pipeline you guys have?

Sairam Srinivas: Thank you, operator. Good morning, everybody. Congratulations on a good quarter and a pretty active one at that. Zach, going back to your comment on potentially exiting Europe entirely, is this something which you could probably expect in 2026? Can you just speak about the broader disposition pipeline you guys have?

Speaker #6: And can you just speak about the broader disposition pipeline you guys have?

Speaker #3: Yeah. I think in terms of exiting Europe, we really what we're left with in Europe is a portfolio of long leased, I think there's over 20 years of remaining lease term on a portfolio of clinics that we own in a joint venture.

Stephanie Karamarkovic: Yeah, I think, in terms of exiting Europe, we really what we're left with in Europe is a portfolio of long leased, I think there's over 20 years of remaining lease term on a portfolio of clinics that we own in a joint venture, and then we have one single asset that we own. look, our goal is to eventually exit Europe. I think the good thing as part of this transaction-

Zachary Vaughan: Yeah, I think, in terms of exiting Europe, we really what we're left with in Europe is a portfolio of long leased, I think there's over 20 years of remaining lease term on a portfolio of clinics that we own in a joint venture, and then we have one single asset that we own. look, our goal is to eventually exit Europe. I think the good thing as part of this transaction that's not captured in the current results and won't flow through likely until mid 2026 to I'm looking at Stephanie, mid 2026 to 2027, is that this transaction takes most of our operating intensive assets out of our portfolio and our teams out of our portfolio that are going with those assets.

Speaker #3: And then we have one single asset that we own. And so look, our goal is to eventually exit Europe. I think the good thing as part of this transaction that that's not captured in the current results and won't flow through likely until mid-2026 to 2027.

Zachary Vaughan: ... that's not captured in the current results and won't flow through likely until mid 2026 to I'm looking at Stephanie, mid 2026 to 2027, is that this transaction takes most of our operating intensive assets out of our portfolio and our teams out of our portfolio that are going with those assets. As this closes over time, it'll vastly simplify and streamline our business. From, it, if you think about like a net cash return on what we're doing in Europe, it's improving, but overall, we still think it makes sense to exit and redeploy the capital here. I would hope it's something that we can execute in 2026. I wouldn't be surprised if perhaps the clinics were something in 2026.

Speaker #3: I'm looking at Stephanie. Mid-2026 to 2027 is that this transaction takes most of our operating intensive assets out of our portfolio and our teams out of our portfolio that are going with those assets.

Speaker #3: So as this closes over time, it'll vastly simplify and streamline our business. And so from if you think about a net cash return, on what we're doing in Europe, it's improving, but overall, we still think it makes sense.

Zachary Vaughan: As this closes over time, it'll vastly simplify and streamline our business. From, it, if you think about like a net cash return on what we're doing in Europe, it's improving, but overall, we still think it makes sense to exit and redeploy the capital here. I would hope it's something that we can execute in 2026. I wouldn't be surprised if perhaps the clinics were something in 2026. I think the single asset, there's certain operational considerations that may just take a little longer.

Speaker #3: To exit and redeploy the capital here. So I would hope it's something that we can execute in 2026. I wouldn't be surprised if perhaps the clinics were something in 2026.

Speaker #3: I think the single asset, there's certain operational considerations that may just take a little longer.

Zachary Vaughan: I think the single asset, there's certain operational considerations that may just take a little longer.

Sairam Srinivas [Director of Research: That's fair. Probably, what about the other markets? Do you think there are other opportunities in Australia or, you know, I guess Australia, maybe South America is probably not an option there.

Speaker #4: That's fair. And probably what about the other markets? Do you think there are other opportunities in Australia or I guess Australia mainly, South America is probably not an option there.

Sairam Srinivas: That's fair. Probably, what about the other markets? Do you think there are other opportunities in Australia or, you know, I guess Australia, maybe South America is probably not an option there.

Speaker #3: Yeah. I think, I mean, I think there's no urgency to do anything there. I think obviously, having resolution to the Healthscope thing, I think, is important because what we're seeing there today is the profitability is improving month by month.

Zachary Vaughan: Yeah, I think, I mean, I think there's no urgency to do anything there. I think, obviously, having resolution to the Healthscope thing, I think is important because what we're seeing there today is the profitability is improving, you know, month by month, in all the assets that we have, like data on, which includes the ones that Vital have and the ones that we have directly. We're seeing liquidity come back to the market, where people are buying smaller assets, but at pretty attractive yields. I think once this Healthscope situations come back, that's when I think you'll see the big scale institutional capital, who likes this asset class, views it as infrastructure-like, but is waiting to see how this pans out.

Zachary Vaughan: Yeah, I think, I mean, I think there's no urgency to do anything there. I think, obviously, having resolution to the Healthscope thing, I think is important because what we're seeing there today is the profitability is improving, you know, month by month, in all the assets that we have, like data on, which includes the ones that Vital have and the ones that we have directly. We're seeing liquidity come back to the market, where people are buying smaller assets, but at pretty attractive yields. I think once this Healthscope situations come back, that's when I think you'll see the big scale institutional capital, who likes this asset class, views it as infrastructure-like, but is waiting to see how this pans out.I think once that happens, then obviously the options for creating even more liquidity in Australia are there.

Speaker #3: In all the assets that we have at data on, which includes the ones that Vital have and the ones that we have directly, we're seeing liquidity come back to the market where people are buying smaller assets, but at pretty attractive yields.

Speaker #3: But I think once this Healthscope situation comes back, that's when I think you'll see the big-scale institutional capital who like this asset class, view it as infrastructure-like, but are waiting to see how this pans out.

Zachary Vaughan: I think once that happens, then obviously the options for creating even more liquidity in Australia are there.

Speaker #3: And I think once that happens, then obviously, the options for creating even more liquidity in Australia are there.

Sairam Srinivas [Director of Research: That's good, Zach. Maybe associated to the dispositions, does that mean there's any other fee income that could probably come on the JV side because of the disposition activity?

Speaker #4: That's perfect. And maybe associated to the dispositions, does that mean there's any other fee income that could probably come on the JV side because of the disposition activity?

Sairam Srinivas: That's good, Zach. Maybe associated to the dispositions, does that mean there's any other fee income that could probably come on the JV side because of the disposition activity?

Speaker #5: Sorry, that wasn't quite clear. Do you mind just repeating the question?

Stephanie Karamarkovic: Sorry, Zach, that wasn't quite clear. Do you mind just repeating the question?

Stephanie Karamarkovic: Sorry, Zach, that wasn't quite clear. Do you mind just repeating the question?

Speaker #4: So as you guys disposed through the JV assets, does that entail a disposition fee from the JV?

Sairam Srinivas [Director of Research: As it is disposed to the JV assets, does that entail a disposition fee from the JV?

Sairam Srinivas: As it is disposed to the JV assets, does that entail a disposition fee from the JV?

Zachary Vaughan: There's not typically disposition fees. More, you know, the JV fees are more ongoing management and service-related fees for things like leasing and capital oversight. No, I don't anticipate that.

Speaker #3: There's not typically disposition fees. The JV fees are more ongoing management and service-related fees for things like leasing and capital oversight. So no, I don't anticipate that.

Zachary Vaughan: There's not typically disposition fees. More, you know, the JV fees are more ongoing management and service-related fees for things like leasing and capital oversight. No, I don't anticipate that.

Speaker #4: All right. And probably my last question, and it's asked, Stephanie, you guys had mentioned getting proportionate debt below 50. That's one of your targets.

Sairam Srinivas [Director of Research: All right. Probably my last question, I know that, Stephanie, you guys had mentioned getting proportionate debt below 50, you know, that's one of your targets. Looking at where it is, you guys are pretty close to getting there, to our basis points on that one. In addition to the sale that you expect to close in the summer this year, are there other levers you intend to pull to kind of get to that number?

Sairam Srinivas: All right. Probably my last question, I know that, Stephanie, you guys had mentioned getting proportionate debt below 50, you know, that's one of your targets. Looking at where it is, you guys are pretty close to getting there, to our basis points on that one. In addition to the sale that you expect to close in the summer this year, are there other levers you intend to pull to kind of get to that number?

Speaker #4: Looking at where it is, you guys are pretty close to getting there—200 basis points on that one. In addition to the sale that you expect to close in the summer this year, are there other levers you intend to pull to kind of get to that number?

Speaker #5: Yeah. So, I think with just what's been announced today between Europe and the Ottawa acquisition, we are anticipating leverage to get below that 50% mark by the completion of those things.

Stephanie Karamarkovic: Yeah. I think with just what's been announced today, between Europe and the Ottawa acquisition, we are anticipating leverage to get below that 50% mark by the completion of those things. We're gonna sit fairly comfortably there. Again, our proceeds today for Europe are earmarked towards further deleveraging. You know, that's the target, and we'll work towards, you know, staying there. Although it could be, you know, lumpy, depending on what other acquisition opportunities we find. We're fairly very committed to staying below 50%.

Stephanie Karamarkovic: Yeah. I think with just what's been announced today, between Europe and the Ottawa acquisition, we are anticipating leverage to get below that 50% mark by the completion of those things. We're gonna sit fairly comfortably there. Again, our proceeds today for Europe are earmarked towards further deleveraging. You know, that's the target, and we'll work towards, you know, staying there. Although it could be, you know, lumpy, depending on what other acquisition opportunities we find. We're fairly very committed to staying below 50%.

Speaker #5: So we’re going to sit fairly comfortably there. Again, our proceeds today for Europe are earmarked towards further deleveraging. But that will be—that’s the target, and it will kind of work towards staying there, although it could be lumpy depending on what other acquisition opportunities we find.

Speaker #5: But we're fairly very committed to staying below 50.

Speaker #4: Awesome, guys. I'll turn it back. Thank you.

Sairam Srinivas [Director of Research: Awesome, guys. I'll turn it back. Thank you.

Sairam Srinivas: Awesome, guys. I'll turn it back. Thank you.

Speaker #1: The next question is from Himanshu Gupta with Scotiabank. Please go ahead.

Operator: The next question is from Himanshu Gupta with Scotiabank. Please go ahead.

Operator: The next question is from Himanshu Gupta with Scotiabank. Please go ahead.

Speaker #4: Thank you and good morning. A lot of updates provided last night. So yeah, so first question will be, on the name change, to vital infrastructure, was this something planned for a while now, or is this something which has been discussed maybe since July last year?

Himanshu Gupta [Director, Equity Research Analyst: Thank you and good morning. Lot of updates provided last night. Yeah, so first question will be on the name change to Vital Infrastructure. Was this something planned for a while now, or is this something which has been discussed, you know, maybe since July last year?

Himanshu Gupta: Thank you and good morning. Lot of updates provided last night. Yeah, so first question will be on the name change to Vital Infrastructure. Was this something planned for a while now, or is this something which has been discussed, you know, maybe since July last year?

Zachary Vaughan: Yeah, I think, you know, I can't comment on whether name changes were discussed in the past. I think it was something that, you know, certainly, you know, I felt that as we're starting to make these changes and transform, that a name change makes sense. We looked at a lot of names. We kept coming back to this one. And, you know, obviously, it's not far off from a business we have a major interest in New Zealand. Look, we think it's a good name for us going forward as we refocus the business. I think whether stuff has happened in the past, it's certainly accelerated.

Speaker #3: Yeah. I think I can't comment on whether name changes were discussed in the past. I think it was something that certainly I felt that as we're starting to make these changes and transform, that a name change makes sense.

Zachary Vaughan: Yeah, I think, you know, I can't comment on whether name changes were discussed in the past. I think it was something that, you know, certainly, you know, I felt that as we're starting to make these changes and transform, that a name change makes sense. We looked at a lot of names. We kept coming back to this one. And, you know, obviously, it's not far off from a business we have a major interest in New Zealand. Look, we think it's a good name for us going forward as we refocus the business. I think whether stuff has happened in the past, it's certainly accelerated.

Speaker #3: We looked at a lot of names we kept coming back to this one. And obviously, it's not far off from a business we have a major interest in in New Zealand, but look, we think it's a good name for us going forward as we refocus the business.

Speaker #3: So I think it whether stuff has happened in the past, it's certainly accelerated. It was one thing we kind of wanted to do was a big objective of ours is sort of reintroduce what we do to the market and felt like let's look at a new name to do that.

Zachary Vaughan: It was one thing we kinda wanted to do was, you know, a big objective of ours is sort of reintroduce what we do to the market and felt like, let's look at a new name to do that. That, that was sort of the. We went through a pretty extensive process to do it, where we came up is the name we're all happy with.

Zachary Vaughan: It was one thing we kinda wanted to do was, you know, a big objective of ours is sort of reintroduce what we do to the market and felt like, let's look at a new name to do that. That, that was sort of the. We went through a pretty extensive process to do it, where we came up is the name we're all happy with.

Speaker #3: And so that was sort of the—so we went through a pretty extensive process to do it, but where we came up is the name we're all happy with.

Speaker #1: Yeah. And does that change the scope of assets you're looking at? A bit beyond healthcare, more into infrastructure, or is it just the name change, nothing, no change in strategy whatsoever?

Himanshu Gupta [Director, Equity Research Analyst: Yeah. Does that change the scope of assets you're looking at? You know, like a bit beyond healthcare, more into infrastructure, or is it just a name change, nothing, no change in strategy whatsoever?

Himanshu Gupta: Yeah. Does that change the scope of assets you're looking at? You know, like a bit beyond healthcare, more into infrastructure, or is it just a name change, nothing, no change in strategy whatsoever?

Speaker #3: Yeah. That's a good question. I think that we look, I would never say that we would I mean, we're going to be opportunistic and try to do the smart things with our capital.

Zachary Vaughan: Yeah, that's a good question. I think that we. Look, I would never say that we would. I mean, we're gonna be opportunistic and try to do the smart things with our capital. I think there's just a big runway for us in Canada, in particular, to really jump out. I mean, we are the leader, clearly here, but I really think we can jump out ahead and really differentiate ourselves. We see a good runway of growth, particularly in healthcare infrastructure in Canada, particularly in delivering that next generation of healthcare infrastructure that's needed. As we look south of the border, I mean, that's an enormous market that it is, again, it's much more liquid, much more transparent, but there's a lot of attractive opportunities out there as well.

Zachary Vaughan: Yeah, that's a good question. I think that we. Look, I would never say that we would. I mean, we're gonna be opportunistic and try to do the smart things with our capital. I think there's just a big runway for us in Canada, in particular, to really jump out. I mean, we are the leader, clearly here, but I really think we can jump out ahead and really differentiate ourselves. We see a good runway of growth, particularly in healthcare infrastructure in Canada, particularly in delivering that next generation of healthcare infrastructure that's needed. As we look south of the border, I mean, that's an enormous market that it is, again, it's much more liquid, much more transparent, but there's a lot of attractive opportunities out there as well.

Speaker #3: I think there's just a big runway for us in Canada in particular to really jump out. I mean, we are the leader clearly here.

Speaker #3: But I really think we can jump out ahead in really differentiate ourselves and we see a good runway of growth, particularly in healthcare infrastructure in Canada, particularly in delivering that next-generation of healthcare infrastructure that's needed.

Speaker #3: And then as we look south of the border, I mean, that's an enormous market that is, again, it's much more liquid, much more transparent but there's a lot of attractive opportunities out there as well.

Speaker #3: And so, I think I wouldn't anticipate, for the time being, you'll see us buying midstream assets or toll roads at the moment. But we are going to stick with healthcare right now.

Zachary Vaughan: I think I wouldn't anticipate for the time being, you'll see us buying midstream assets or toll roads at the moment. We are gonna stick with healthcare right now, and I think for the foreseeable future. I think our goal is to really be kind of a pure play, North American-centric leader in this space.

Zachary Vaughan: I think I wouldn't anticipate for the time being, you'll see us buying midstream assets or toll roads at the moment. We are gonna stick with healthcare right now, and I think for the foreseeable future. I think our goal is to really be kind of a pure play, North American-centric leader in this space.

Speaker #3: And I think, for the foreseeable future, our goal is to really be kind of a pure-play, North American-centric leader in this space.

Speaker #4: All right. Thank you. And then on this European portfolio sale to TPG, how competitive was the process? And did you get the price you were looking for?

Himanshu Gupta [Director, Equity Research Analyst: Got it. Thank you. Then on this European portfolio sale to TPG, how competitive was the process? Did you get the price you were looking for? How did that compare to IFRS?

Himanshu Gupta: Got it. Thank you. Then on this European portfolio sale to TPG, how competitive was the process? Did you get the price you were looking for? How did that compare to IFRS?

Speaker #4: I mean, how did that compare to IFS?

Speaker #3: Well, I'd say I never quite get the price I'm looking for, including at any given time. But I'm going to let my comments on that.

Zachary Vaughan: Well, I'd say I never quite get the price I'm looking for, including, you know, at any given time. I'm gonna let Matt comment on that.

Zachary Vaughan: Well, I'd say I never quite get the price I'm looking for, including, you know, at any given time. I'm gonna let Matt comment on that.

[Company Representative] (Northwest Healthcare Properties): Yeah, Himanshu, good morning. It was a widely marketed process, and we received many very competitive bids. Ultimately, TPG were a strong bidder, and we're in a position to move at our pace, and so we were very happy to be able to reach agreement with them. Yeah, I mean, all in all, as Zach said, you always would like to sell for more, but we're happy with the outcome.

Mike Brady: Yeah, Himanshu, good morning. It was a widely marketed process, and we received many very competitive bids. Ultimately, TPG were a strong bidder, and we're in a position to move at our pace, and so we were very happy to be able to reach agreement with them. Yeah, I mean, all in all, as Zach said, you always would like to sell for more, but we're happy with the outcome.

Speaker #6: Yeah. Himanshu, good morning. It was a widely marketed process, and we received many very competitive bids. And ultimately, TPG were a strong bidder and were in a position to move at our pace.

Speaker #6: And so we were very happy to be able to reach agreement with them. And yeah, I mean, all in all, as Zach said, you always would like to sell for more, but we're happy with the outcome.

Speaker #3: Yeah. I think it was I'd say the given that we were selling essentially making available an entity including an operating business to manage multi-tenant assets, do some leasing, do some capital projects, and things like that, it probably lent itself more towards a group like a TPG who's highly sophisticated, private equity capital.

Zachary Vaughan: Yeah, I think it was, you know, I'd say that the, given that we were selling, essentially making available an entity, including an operating business, to manage multi-tenant assets, do some leasing, do some capital projects and things like that, it probably lent itself more towards a group like a TPG, who's highly sophisticated, private equity capital. That's really what we saw. We saw no shortage of it, really coming out there. They certainly were able to move fast and have access to the kind of capital that they needed to do this.

Zachary Vaughan: Yeah, I think it was, you know, I'd say that the, given that we were selling, essentially making available an entity, including an operating business, to manage multi-tenant assets, do some leasing, do some capital projects and things like that, it probably lent itself more towards a group like a TPG, who's highly sophisticated, private equity capital. That's really what we saw. We saw no shortage of it, really coming out there. They certainly were able to move fast and have access to the kind of capital that they needed to do this.

Speaker #3: And that's really what we saw. We saw no shortage of it. Really, really, really coming out there. But they certainly were able to move fast and have access to the kind of capital that they needed to do this.

Speaker #4: Got it. So Sethy, I mean, 9 to 10 percent adjustment, is that fair on the assets on Europe which you took in Q4?

Himanshu Gupta [Director, Equity Research Analyst: Correct. Stephanie, I mean, 9% to 10% adjustment, is that fair on the assets on Europe, which you took in Q4?

Himanshu Gupta: Correct. Stephanie, I mean, 9% to 10% adjustment, is that fair on the assets on Europe, which you took in Q4?

Speaker #7: Yeah. I think your math is right. If you look at segmentally, our European write-down during the quarter, that represents about 9% of the portfolio there pre-adjustment.

Stephanie Karamarkovic: Yeah, I think your math is right. If you look at segmentally, our European write-down during the quarter, that represents about 9% of the portfolio there pre-adjustment. That's fairly representative of the discount.

Stephanie Karamarkovic: Yeah, I think your math is right. If you look at segmentally, our European write-down during the quarter, that represents about 9% of the portfolio there pre-adjustment. That's fairly representative of the discount.

Speaker #7: So that's fairly representative of the discount.

Speaker #4: Okay. And just one last follow-up. And Sethy, you mentioned this to be earnings neutral. I mean, given the cost of debt you had on wholly owned portfolio, which is pretty low, how do you get to that math?

Himanshu Gupta [Director, Equity Research Analyst: Okay. Just one last follow-up. Stephanie, you mentioned this to be earnings neutral.

Himanshu Gupta: Okay. Just one last follow-up. Stephanie, you mentioned this to be earnings neutral.I mean, given the cost of debt you had on, wholly on portfolio, which is pretty low, like, how do you get to that math? I mean, you need to have a lot of G&A savings to do that. Is that what is driving bulk of that earnings neutral outcome?

Stephanie Karamarkovic: Mm-hmm.

Himanshu Gupta [Director, Equity Research Analyst: I mean, given the cost of debt you had on, wholly on portfolio, which is pretty low, like, how do you get to that math? I mean, you need to have a lot of G&A savings to do that. Is that what is driving bulk of that earnings neutral outcome?

Speaker #4: I mean, you need to have a lot of G&A savings to do that. Is that what is driving the bulk of that earnings-neutral outcome?

Stephanie Karamarkovic: Yeah, absolutely. As Zach mentioned, you know, as a result of this, we're left with a very, you know, a portfolio of assets that are, you know, triple net, leased for 20 years and not very management intensive. It allows us to reduce our platform there quite significantly. Really, we'll see most of the G&A in Europe being reduced over the course of the year. Between that, again, we'll be using the proceeds to pay down the Series H debentures, is our goal. Those are sitting at 6.25%. That, again, kind of adds to the accretion analysis. Yes, we believe it's neutral.

Speaker #7: Yeah. Yeah. Absolutely. So as Zach mentioned, as a result of this, we're left with a very a portfolio of assets that are triple net, leased for 20 years, and not very management-intensive.

Stephanie Karamarkovic: Yeah, absolutely. As Zach mentioned, you know, as a result of this, we're left with a very, you know, a portfolio of assets that are, you know, triple net, leased for 20 years and not very management intensive. It allows us to reduce our platform there quite significantly. Really, we'll see most of the G&A in Europe being reduced over the course of the year. Between that, again, we'll be using the proceeds to pay down the Series H debentures, is our goal. Those are sitting at 6.25%. That, again, kind of adds to the accretion analysis. Yes, we believe it's neutral.

Speaker #7: So it allows us to reduce our platform there quite significantly. And so really, we'll see most of the GNA in Europe being reduced over the course of the year.

Speaker #7: And between that, again, we'll be using the proceeds to pay down the Series H to Ventures is our goal. So those are sitting at 6.25%.

Speaker #7: So that, again, kind of adds to the accretion analysis. But yes, we believe it's neutral.

Speaker #4: Awesome. Okay. Thank you so much. And I'll turn it back.

Himanshu Gupta [Director, Equity Research Analyst: Awesome. Okay, thank you so much, and I'll turn it back.

Himanshu Gupta: Awesome. Okay, thank you so much, and I'll turn it back.

Zachary Vaughan: Yeah, I think just to add to that, when you think about the intensity, I think we have tenants in the portfolio, Tracey, this year. It's like, I think it's over 400 tenants in Europe alone. That's gonna fall... Like, effectively, it's gonna fall to two.

Zachary Vaughan: Yeah, I think just to add to that, when you think about the intensity, I think we have tenants in the portfolio, Tracey, this year. It's like, I think it's over 400 tenants in Europe alone. That's gonna fall... Like, effectively, it's gonna fall to two.

Speaker #3: Yeah. Just to add to that, when you think about the intensity, I think we have tenants in the portfolio, Tracy's here. It's like I think it's over 400 tenants in Europe, alone.

Speaker #3: And that's going to fall. Effectively, it's going to fall to two.

Speaker #4: Got it. Okay. Thank you, Zach. And thanks so much, Zach. Thank you.

Himanshu Gupta [Director, Equity Research Analyst: Got it. Okay. Thank you, Zach, and thanks once again.

Himanshu Gupta: Got it. Okay. Thank you, Zach, and thanks once again.

Zachary Vaughan: Yeah, thank you.

Zachary Vaughan: Yeah, thank you.

Giuliano Taddeo: The next question is from Giuliano Taddeo, with National Bank. Please go ahead.

Operator: The next question is from Giuliano Taddeo, with National Bank. Please go ahead.

Speaker #1: The next question is from Juliano Thornhill with National Bank. Please go ahead.

Speaker #8: Hey, guys. Good morning, everyone. I just kind of had a quick question on the operating priorities, I guess, first. I know you outlined in your deck there.

Giuliano Taddeo: Hey, guys. Good morning, everyone.

Giuliano Thornhill: Hey, guys. Good morning, everyone.

Zachary Vaughan: Hey.

Zachary Vaughan: Hey.

Giuliano Taddeo: Uh, I just-

Giuliano Thornhill: Uh, I just-

Stephanie Karamarkovic: Good morning.

Stephanie Karamarkovic: Good morning.

Giuliano Taddeo: Just kind of had a quick questions on the operating priorities, I guess, first? I know you outlined in your deck there, do you, do you envision that, you know, shifting at all? Like, is that the long-term, kind of outlook, would you say? Just because your remain co-business could be different than the current one.

Giuliano Thornhill: Just kind of had a quick questions on the operating priorities, I guess, first? I know you outlined in your deck there, do you, do you envision that, you know, shifting at all? Like, is that the long-term, kind of outlook, would you say? Just because your remain co-business could be different than the current one.

Speaker #8: Do you envision that shifting at all? Is that the long-term kind of outlook, would you say, just because you're remain co-business could be different than the current one?

Speaker #7: Yeah. Are you speaking to the shifting in the regional split of our portfolio?

Stephanie Karamarkovic: Yeah, are you speaking to the shifting in, like, the regional split of our portfolio?

Stephanie Karamarkovic: Yeah, are you speaking to the shifting in, like, the regional split of our portfolio?

Giuliano Taddeo: Yeah, your outlook of 3% to 4% same property NOI growth and the less than 9x debt to EBITDA-

Giuliano Thornhill: Yeah, your outlook of 3% to 4% same property NOI growth and the less than 9x debt to EBITDA-

Speaker #8: Yeah, yeah. Your outlook of three to four percent same property NOI growth, and then less than nine times debt to EBITDA, and like 96% occupancy.

Stephanie Karamarkovic: Yeah.

Stephanie Karamarkovic: Yeah.

Giuliano Taddeo: The, like, 96% occupancy. I'm just wondering, like, is that the long-term outlook that you're sticking towards? Can it change with, you know, the dispositions that are coming?

Giuliano Thornhill: The, like, 96% occupancy. I'm just wondering, like, is that the long-term outlook that you're sticking towards? Can it change with, you know, the dispositions that are coming?

Speaker #8: I'm just wondering, is that the long-term outlook that you're sticking towards? Or can it change with the dispositions that are coming?

Speaker #7: I don't think the dispositions that are coming will impact it. I think what we're left with will continue to deliver those metrics. I think as we shift our portfolio and we move into more of these infrastructure-like assets, we'll likely get longer lease terms and kind of more steady SPNOI.

Stephanie Karamarkovic: ... I don't think the dispositions that are coming will impact it. I think what we're left with will continue to deliver those metrics. I think as we shift our portfolio and we move into more of these infrastructure-like assets, we'll likely get longer lease terms and kind of more steady SPNOI, which could change over time. But again, won't be material in the next few years. It'll kind of take some time to ramp up over time. Yeah, we're fairly confident that the metrics that we have there targeted reflect what the portfolio will look like over the coming years.

Stephanie Karamarkovic: ... I don't think the dispositions that are coming will impact it. I think what we're left with will continue to deliver those metrics. I think as we shift our portfolio and we move into more of these infrastructure-like assets, we'll likely get longer lease terms and kind of more steady SPNOI, which could change over time. But again, won't be material in the next few years. It'll kind of take some time to ramp up over time. Yeah, we're fairly confident that the metrics that we have there targeted reflect what the portfolio will look like over the coming years.

Speaker #7: Which could change over time. But again, it won't be material in the next few years. It'll kind of take some time to ramp up over time.

Speaker #7: So yeah, we're fairly confident that the metrics that we have there targeted reflect what the portfolio will look like over the coming years.

Speaker #3: Yeah, I think, Julian, one thing to note is if you look at our composition today, it's heavily, I'd say, weighted towards inpatient assets. We do own a lot of large hospitals in Australia and elsewhere.

Zachary Vaughan: Yeah, I think, Juliana, one thing to note is, if you look at our composition today, it's heavily, I'd say, weighted towards inpatient assets. We do own a lot of large hospitals in Australia and elsewhere. I think as we reallocate capital and start growing, we're focused more on the outpatient side. Those long leased assets Stephanie mentioned in Canada are outpatient. I wouldn't anticipate we would do anything of any materiality in the US that was inpatient. It'll all be outpatient. I think you'll see that kind of proportion shift over time. Generally, we're still targeting the same kind of performance.

Zachary Vaughan: Yeah, I think, Juliana, one thing to note is, if you look at our composition today, it's heavily, I'd say, weighted towards inpatient assets. We do own a lot of large hospitals in Australia and elsewhere. I think as we reallocate capital and start growing, we're focused more on the outpatient side. Those long leased assets Stephanie mentioned in Canada are outpatient. I wouldn't anticipate we would do anything of any materiality in the US that was inpatient. It'll all be outpatient. I think you'll see that kind of proportion shift over time. Generally, we're still targeting the same kind of performance.

Speaker #3: And I think as we reallocate capital and start growing, we're focused more on the outpatient side. So those long-leased assets Stephanie mentioned in Canada are outpatient.

Speaker #3: And I wouldn't anticipate we would do anything any materiality in the US that was inpatient. It'll all be outpatient. And so I think you'll see that shift that kind of proportion shift over time.

Speaker #3: But generally, we're still targeting the same kind of performance.

Speaker #8: Okay. And I guess just moving to that outpatient opportunity, how large or could you put a number on it, do you think, is either that development or acquisition opportunity within Canada related to hospitals?

Giuliano Taddeo: Okay. I guess just moving to that outpatient opportunity, how large or could you put a number on it, do you think, is either that development or acquisition opportunity within Canada, like, related to hospitals? Do you have a sense for that right now?

Giuliano Thornhill: Okay. I guess just moving to that outpatient opportunity, how large or could you put a number on it, do you think, is either that development or acquisition opportunity within Canada, like, related to hospitals? Do you have a sense for that right now?

Speaker #8: And do you have a sense for that right now?

Speaker #3: Yeah, I think Dave Casimiro, our EVP, sort of leads the charge on all this. He's actually meeting with a hospital right now, so he's not available on this call.

Zachary Vaughan: Yeah, I think Dave Casimiro, our EVP, who sort of leads the charge on all this, he's actually meeting with a hospital right now, so he's not available on this call. I think if you were to say, what do we think? I mean, the opportunity, I mean, we've seen things, if you need CAD 30 billion-plus of this stuff in Canada. I think the reality is, it's hard to say because it is, at the moment, somewhat driven by the leadership of the specific hospitals and, you know, their kind of ability to go and be forward-thinking and, you know, be commercial. Our pipeline today, I mean, I'd say we're actively in discussions on, you know, CAD half a billion to a billion of similar assets today.

Zachary Vaughan: Yeah, I think Dave Casimiro, our EVP, who sort of leads the charge on all this, he's actually meeting with a hospital right now, so he's not available on this call. I think if you were to say, what do we think? I mean, the opportunity, I mean, we've seen things, if you need CAD 30 billion-plus of this stuff in Canada. I think the reality is, it's hard to say because it is, at the moment, somewhat driven by the leadership of the specific hospitals and, you know, their kind of ability to go and be forward-thinking and, you know, be commercial. Our pipeline today, I mean, I'd say we're actively in discussions on, you know, CAD half a billion to a billion of similar assets today.

Speaker #3: But I think if you were to say, "What do we think?" I mean, the opportunity should be I mean, we've seen things of you need $30 billion plus of this stuff in Canada.

Speaker #3: But I think the reality is, it's hard to say because, at the moment, it's somewhat driven by the leadership of the specific hospitals.

Speaker #3: And they're kind of ability to go and be forward-thinking and be commercial. Our pipeline today, I mean, I'd say we're actively in discussions on half a billion to a billion of similar assets today these things just I'd say unlike whether it's a logistics tenant who sends out an RFP and sort of wants something in six months, these things take a long time to curate.

Zachary Vaughan: These things just, you know, I'd say unlike, whether it's a logistics tenant who sends out an RFP and sort of wants something in six months, these things take a long time to curate. I do think it could be a very material thing for us going forward, that kind of keeps accelerating with every deal, is kind of how it works. I mean, it was the success of Lakeridge that drew this hospital CEO to say, 'Wait a minute, how did they do that?'

Zachary Vaughan: These things just, you know, I'd say unlike, whether it's a logistics tenant who sends out an RFP and sort of wants something in six months, these things take a long time to curate. I do think it could be a very material thing for us going forward, that kind of keeps accelerating with every deal, is kind of how it works. I mean, it was the success of Lakeridge that drew this hospital CEO to say, 'Wait a minute, how did they do that?'

Speaker #3: But I do think it could be a very material thing for us going forward that we'll that kind of keeps accelerating with every deal is kind of how it works.

Speaker #3: I mean, it was a success of Lakeridge that drew this hospital CEO to say, "Wait a minute. How did they do that?" That's something I want to look at.

Zachary Vaughan: That's something I want to look at. I think it will accelerate, but, you know, I don't think we're at a point now where, we're exhausted in our capacity or have to go find partners or kind of additional capital to do it yet.

Zachary Vaughan: That's something I want to look at. I think it will accelerate, but, you know, I don't think we're at a point now where, we're exhausted in our capacity or have to go find partners or kind of additional capital to do it yet.

Speaker #3: So I think it will accelerate, but I don't think we're at a point now where we're exhausted in our capacity or have to go find partners or kind of additional capital to do it.

Speaker #3: Yet.

Speaker #8: Right. And as this kind of outpatient trend accelerates or picks up, how could that impact your kind of existing tenant base and business within Canada?

Giuliano Taddeo: Right. As this kind of outpatient trend accelerates or picks up, how could that impact your kind of existing tenant base and businesses in Canada? Is there, you know, is potentially are physicians kind of going to be pressured because there's more competition? Is there any, do you have a sense of kind of what the risks are there to your business?

Giuliano Thornhill: Right. As this kind of outpatient trend accelerates or picks up, how could that impact your kind of existing tenant base and businesses in Canada? Is there, you know, is potentially are physicians kind of going to be pressured because there's more competition? Is there any, do you have a sense of kind of what the risks are there to your business?

Speaker #8: Is there potentially our physicians kind of going to be pressured because there's more competition? Is there any do you have a sense of kind of what the risks are there to your business?

Speaker #3: Yeah. Everything we own in Canada is essentially outpatient. So there's no risk there. I think, in fact, the changes they're making, particularly to sort of general practitioners and family doctors, where they're basically going to make it more favorable for them to be in that line of healthcare work, actually improve our existing assets, which are geared towards that.

Zachary Vaughan: Yeah, I, everything we own in Canada is essentially outpatient, so there's no risk there. I think, in fact, the changes they're making, particularly to sort of general practitioners and family doctors, where they're basically gonna make it more favorable for them to be in that line of healthcare work, actually, improve our existing assets, which are geared towards that. I think what we will see, and that we're working with groups with, is there's a big push on community healthcare, where basically, it could be as simple as, you know, in our buildings, we have 30 tenants, and 15 of them kind of join together and create a community health center in our asset. What it would mean is that effectively we end up with 1 tenant on the lease, as opposed to 15 or 20.

Zachary Vaughan: Yeah, I, everything we own in Canada is essentially outpatient, so there's no risk there. I think, in fact, the changes they're making, particularly to sort of general practitioners and family doctors, where they're basically gonna make it more favorable for them to be in that line of healthcare work, actually, improve our existing assets, which are geared towards that. I think what we will see, and that we're working with groups with, is there's a big push on community healthcare, where basically, it could be as simple as, you know, in our buildings, we have 30 tenants, and 15 of them kind of join together and create a community health center in our asset. What it would mean is that effectively we end up with 1 tenant on the lease, as opposed to 15 or 20.

Speaker #3: I think what we will see and that we're working with groups with is there's a big push on community healthcare. Where basically, it could be as simple as in our buildings, we have 30 tenants and 15 of them kind of joined together and create a community health center in our asset.

Speaker #3: What it would mean is that effectively, we end up with one tenant. On the lease, as opposed to 15 or 20. So inherently, we sort of have better credit, yet you have all the individual practitioners behind the lease.

Zachary Vaughan: Inherently, we sort of have better credit, yet you have all the.

Zachary Vaughan: Inherently, we sort of have better credit, yet you have all the.

Giuliano Taddeo: Right.

Zachary Vaughan: all the individual practitioners behind the lease. That's a trend we're starting to see. I think if you were to compare it to the US, I think our average tenant size, again, I wish Dave were here to answer this, but is around, I don't know, a little over 1,000 sq ft. If you were to compare it to the same outpatient things in the US, it's probably closer to 4,500 sq ft, where that model exists, where physicians kind of partner together into more sort of family medical groups. I think that will happen. I don't think it. In fact, I think it will benefit our real estate over time, and puts us in a great position because we already have all those uses in the asset.

Giuliano Thornhill: Right.

Zachary Vaughan: all the individual practitioners behind the lease. That's a trend we're starting to see. I think if you were to compare it to the US, I think our average tenant size, again, I wish Dave were here to answer this, but is around, I don't know, a little over 1,000 sq ft. If you were to compare it to the same outpatient things in the US, it's probably closer to 4,500 sq ft, where that model exists, where physicians kind of partner together into more sort of family medical groups. I think that will happen. I don't think it. In fact, I think it will benefit our real estate over time, and puts us in a great position because we already have all those uses in the asset.

Speaker #3: That's a trend we're starting to see. And I think if you were to compare it to the US, I think our average tenant size, again, I wish Dave were here to answer this.

Speaker #3: But it's around, I don't know, a little over 1,000 square feet. And if you were to compare it to the same outpatient things in the US, it's probably closer to 4,500 square feet, where that model exists, where physicians kind of partner together into more sort of family medical groups.

Speaker #3: So I think that will happen. I don't think it in fact, I think it will benefit our real estate over time. And puts us in a great position because we already have all those uses in the asset.

Speaker #8: And the tenant scale wouldn't be a risk to kind of leasing dynamics for yourselves as in thinking about get better rents or lower rents, mind you?

Giuliano Taddeo: The tenant scale wouldn't be a risk to kind of leasing dynamics for yourselves, as in, making you get better rents, or lower rents, mind you?

Giuliano Thornhill: The tenant scale wouldn't be a risk to kind of leasing dynamics for yourselves, as in, making you get better rents, or lower rents, mind you?

Zachary Vaughan: I don't think so. I mean, I think the, you know, I think if we look at our Canadian assets, generally, I mean, there's been a bit of noise around some movements around operationally, but, you know, that we tend to get 3-ish%, 3% to 4% rent growth a year. I don't think that would change, and I don't think an 800 sq ft tenant moving to be a 4,500 sq ft tenant would materially impact either their ability to move us or not.

Speaker #3: I don't think so. I mean, I think the I think if we look at our Canadian assets generally, I mean, there's been a bit of noise around some movements around operationally.

Zachary Vaughan: I don't think so. I mean, I think the, you know, I think if we look at our Canadian assets, generally, I mean, there's been a bit of noise around some movements around operationally, but, you know, that we tend to get 3-ish%, 3% to 4% rent growth a year. I don't think that would change, and I don't think an 800 sq ft tenant moving to be a 4,500 sq ft tenant would materially impact either their ability to move us or not.

Speaker #3: But we tend to get 3-ish percent, 3 to 4 percent rent gross a year. And I don't think that would change. And I don't think an 800-square-foot tenant moving to be a 4,500-square-foot tenant would materially impact either their ability to move us or not.

Zachary Vaughan: I think the question could be, if we were to look out a few years, and all of a sudden we had billions of this new stuff in this new kind of healthcare infrastructure in production, to the extent all of a sudden, you know, it got highly competitive, then that may change our outlook, but we have a long runway till that happens.

Speaker #3: I think the question could be if we were to look out a few years, and all of a sudden, we had billions of these new stuff in this new kind of healthcare infrastructure in production, to the extent all of a sudden, it got highly competitive, then that would that may change our outlook.

Zachary Vaughan: I think the question could be, if we were to look out a few years, and all of a sudden we had billions of this new stuff in this new kind of healthcare infrastructure in production, to the extent all of a sudden, you know, it got highly competitive, then that may change our outlook, but we have a long runway till that happens.

Speaker #3: But we have a long runway until that happens.

Speaker #8: Okay. All right. Thanks, guys. I'll jump back in the queue.

Giuliano Taddeo: Okay. All right. Thanks, guys. I'll jump back in the queue.

Giuliano Thornhill: Okay. All right. Thanks, guys. I'll jump back in the queue.

Speaker #3: Thanks.

Zachary Vaughan: Thanks.

Zachary Vaughan: Thanks.

Speaker #9: Once again, if you have a question, please press star, then one. The next question is from Palmy Burr with RBC Capital Markets. Please go ahead.

Operator: Once again, if you have a question, please press Star then One. The next question is from Pammi Bir with RBC Capital Markets. Please go ahead.

Operator: Once again, if you have a question, please press Star then One. The next question is from Pammi Bir with RBC Capital Markets. Please go ahead.

Speaker #10: Hi. Good morning. Just wanted to come back to the European asset sale. Initially, I think we were thinking that it was perhaps just the wholly owned assets or a portion thereof.

Alyssa Barry: Hi, good morning. Just wanted to come back to the European asset sale. Initially, I think, you know, we were thinking that it was perhaps just the wholly owned assets or a portion thereof, but it looks like, you know, you've got the JV, some of the JV assets in there too. I'm just curious, can you maybe just expand on the evolution of that transaction?

Pammi Bir: Hi, good morning. Just wanted to come back to the European asset sale. Initially, I think, you know, we were thinking that it was perhaps just the wholly owned assets or a portion thereof, but it looks like, you know, you've got the JV, some of the JV assets in there too. I'm just curious, can you maybe just expand on the evolution of that transaction?

Speaker #10: But it looks like you've got some of the JV assets in there too. So I'm just curious, can you maybe just expand on the evolution of that transaction?

Speaker #3: Yeah. I think we that's a good question, Paul. I mean, we started out initially with the idea of really our assets just in Germany, just in the outpatient sector.

Zachary Vaughan: Yeah, I think we. That's a good question, Pammi. We started out initially with the idea of really our assets just in Germany, just in the outpatient sector. What we realized is that, you know, a little more scale would be beneficial, and our assets in the Netherlands were probably closer to outpatient in that they had varying remaining lease terms, even though in some cases you had some larger attendant clinics.

Zachary Vaughan: Yeah, I think we. That's a good question, Pammi. We started out initially with the idea of really our assets just in Germany, just in the outpatient sector. What we realized is that, you know, a little more scale would be beneficial, and our assets in the Netherlands were probably closer to outpatient in that they had varying remaining lease terms, even though in some cases you had some larger attendant clinics.

Speaker #3: What we realized is that a little more scale would be beneficial. And our assets in the Netherlands were probably closer to outpatient in that they had varying remaining lease terms, even though in some cases you had some larger attendant clinics.

Speaker #3: And so we worked with our partner and said, "Look, it may make sense to sort of put this together and take it out." So essentially, it became I say more of an exit of a certain type of asset.

Zachary Vaughan: We worked with our partner and said, Look, it may make sense to sort of put this together and take it out. Essentially, it became, I'd say, more of an exit of a certain type of asset, in that what we're left with primarily is, again, we have one asset that's not, that wasn't part of the sale perimeter, that we have some stuff to do and then we'll exit. Everything else we're left with is just the clinics in our joint venture that are long-term, triple net lease, to essentially one, I think essentially one tenant. That's kind of how it sort of came together.

Zachary Vaughan: We worked with our partner and said, Look, it may make sense to sort of put this together and take it out. Essentially, it became, I'd say, more of an exit of a certain type of asset, in that what we're left with primarily is, again, we have one asset that's not, that wasn't part of the sale perimeter, that we have some stuff to do and then we'll exit. Everything else we're left with is just the clinics in our joint venture that are long-term, triple net lease, to essentially one, I think essentially one tenant. That's kind of how it sort of came together.

Speaker #3: In that what we're left with primarily is, again, we have one asset that's not that wasn't part of the sale perimeter that we have some stuff to do.

Speaker #3: And then we'll exit. But then everything else we're left with is just the clinics in our joint venture that are long-term triple net leases to essentially one I think essentially one tenant.

Speaker #3: And so that's kind of how it sort of came together. I mean, Mike's here and obviously did a great job and kind of getting everything together.

Zachary Vaughan: Obviously, I mean, Mike's here and obviously did a great job in kind of getting everything together, but it was complicated and that, you know, you have assets from different pools of capital. We had to make sure that, you know, that things were transparent. We worked hand in hand with our joint venture partner, who did an exceptional job, with us, moving very quickly to get this done. That's kind of how it evolved. It was more driven by, initially our desire to say maybe we wanna get out of that portfolio, and then we added some to it, but then said we just didn't think the clinics, in addition to that, they're sort of a different profile. They're probably more of a credit-oriented, single tenant, net lease profile buyer than-

Zachary Vaughan: Obviously, I mean, Mike's here and obviously did a great job in kind of getting everything together, but it was complicated and that, you know, you have assets from different pools of capital. We had to make sure that, you know, that things were transparent. We worked hand in hand with our joint venture partner, who did an exceptional job, with us, moving very quickly to get this done. That's kind of how it evolved. It was more driven by, initially our desire to say maybe we wanna get out of that portfolio, and then we added some to it, but then said we just didn't think the clinics, in addition to that, they're sort of a different profile. They're probably more of a credit-oriented, single tenant, net lease profile buyer than-

Speaker #3: But it was complicated in that you have assets from different pools of capital. We had to make sure that that things were transparent. But we worked hand in hand with our joint venture partner who did an exceptional job with us moving very quickly to get this done.

Speaker #3: But that's kind of how it evolved. It was more driven by initially our desire to say maybe we want to get out of that portfolio and then we added some to it.

Speaker #3: But then said, "We just didn't think the clinics in addition to that, they're sort of a different profile. They're probably more of a credit-oriented single tenant net lease profile buyer than what the bulk of our portfolio was."

Alyssa Barry: Right.

Pammi Bir: Right.

Zachary Vaughan: Than what the bulk of our portfolio is.

Zachary Vaughan: Than what the bulk of our portfolio is.

Speaker #10: And to clarify, your partner has exited those assets as well that are part of the deal.

Alyssa Barry: To clarify, your partner has exited those assets as well that are part of the deal?

Pammi Bir: To clarify, your partner has exited those assets as well that are part of the deal?

Zachary Vaughan: They've exited the... Yes. They're...

Speaker #3: They've exited. Yes. They're going to exit with us.

Zachary Vaughan: They've exited the... Yes. They're...

Alyssa Barry: Yeah.

Pammi Bir: Yeah.

Zachary Vaughan: They're gonna exit with us.

Zachary Vaughan: They're gonna exit with us.

Speaker #10: Right. Okay. And then Zach, just in your letter, you talked about the growth in the US or potentially redeploying capital into the US and identifying a, I guess, strategic transaction.

Alyssa Barry: Right. Okay.

Pammi Bir: Right. Okay.

Zachary Vaughan: Right.

Zachary Vaughan: Right.

Alyssa Barry: Zach, just in your letter, you know, you talked about the growth in the US or potentially redeploying capital into the US, identifying a, I guess, strategic transaction. Can you maybe expand on that, maybe where are you in that process? I guess the second part to that is, do the current US assets fit into, I guess, that objective?

Pammi Bir: Zach, just in your letter, you know, you talked about the growth in the US or potentially redeploying capital into the US, identifying a, I guess, strategic transaction. Can you maybe expand on that, maybe where are you in that process? I guess the second part to that is, do the current US assets fit into, I guess, that objective?

Speaker #10: Can you maybe expand on that, and maybe where are you in that process? And then I guess the second part to that is, do the current US assets fit into, I guess, that objective?

Speaker #3: Yeah. I think I mean, I've said before I'd start with the current assets, Palmy, in that if I had my way, I wish I didn't have them and I could start with a blank slate.

Zachary Vaughan: Yeah, I think, I mean, I've said before, I'd start with the current assets, Pammi. If I had my way, I wish I we didn't have them. I could start with a blank slate. I don't think there's a lot. That portfolio, though the assets are fine, it's a disparate group. It's a mix of asset types. I think as we look forward, we wanna focus on outpatient surgery, to a small extent, inpatient rehab. The US is, although it's extraordinarily liquid and transparent, the assets are pretty small. Like a $50 million outpatient asset or surgery center is pretty rare, just in terms of how decentralized the health system is.

Zachary Vaughan: Yeah, I think, I mean, I've said before, I'd start with the current assets, Pammi. If I had my way, I wish I we didn't have them. I could start with a blank slate. I don't think there's a lot. That portfolio, though the assets are fine, it's a disparate group. It's a mix of asset types. I think as we look forward, we wanna focus on outpatient surgery, to a small extent, inpatient rehab. The US is, although it's extraordinarily liquid and transparent, the assets are pretty small. Like a $50 million outpatient asset or surgery center is pretty rare, just in terms of how decentralized the health system is.

Speaker #3: I don't think there's a lot. That portfolio or the assets are fine. There's not it's a disparate group. And it's a mix of asset types.

Speaker #3: And so I think as we look forward, we want to focus on outpatient surgery and to a small extent inpatient rehab. And the US is although it's extraordinarily liquid and transparent, the assets are pretty small.

Speaker #3: Like a $50 million outpatient asset or surgery center is pretty rare. Just in terms of how decentralized the health system is. And so my view has always been that we need to be in the US to grow.

Zachary Vaughan: My view has always been that we need to be in the US to grow. It's an enormous investable universe. It has the same underlying underlying demographics, but in order to do it, we really need, I can't have people flying out of Toronto, trying to buy assets and kind of run assets. We need a pretty deep position there that'll let us have the right kind of relationships with the health systems, the right access to transactions. If you think about it, even the volume of transactions that happens there is large. It's a very fragmented market, and you really have to be there to take advantage of the opportunities.

Zachary Vaughan: My view has always been that we need to be in the US to grow. It's an enormous investable universe. It has the same underlying underlying demographics, but in order to do it, we really need, I can't have people flying out of Toronto, trying to buy assets and kind of run assets. We need a pretty deep position there that'll let us have the right kind of relationships with the health systems, the right access to transactions. If you think about it, even the volume of transactions that happens there is large. It's a very fragmented market, and you really have to be there to take advantage of the opportunities.

Speaker #3: It's an enormous investable universe. It has the same underlying demographics. But in order to do it, we really need I can't have people flying out of Toronto trying to buy assets and kind of run assets.

Speaker #3: We need a pretty deep position there that'll let us have the right kind of relationships with the health systems, the right access to transactions.

Speaker #3: And if you think about it, even the volume of transactions that happens there is large. It's very fragmented market. And you really have to be there to take advantage of the opportunities.

Speaker #3: And so again, we're exploring everything from strategic transactions, which could involve an M&A type of deal to sort of more strategic alignment or acquisition of a group of call them healthcare infrastructure asset managers.

Zachary Vaughan: Again, we're exploring everything from strategic transactions, which could involve an M&A type of deal. To, you know, sort of, you know, more strategic alignment or acquisition of a group of, you know, call them, healthcare infrastructure asset managers, to really help us grow. Because ideally, what we want is an entity or group that will help us make very repeatable, simple, repeatable investments. With very low friction, and have the relationships with the health systems we need to continue to kind of grow the portfolio. That's where we are. We've been meeting people. I mean, obviously, we've had a lot to do just in the existing portfolio.

Zachary Vaughan: Again, we're exploring everything from strategic transactions, which could involve an M&A type of deal. To, you know, sort of, you know, more strategic alignment or acquisition of a group of, you know, call them, healthcare infrastructure asset managers, to really help us grow. Because ideally, what we want is an entity or group that will help us make very repeatable, simple, repeatable investments. With very low friction, and have the relationships with the health systems we need to continue to kind of grow the portfolio. That's where we are. We've been meeting people. I mean, obviously, we've had a lot to do just in the existing portfolio.

Speaker #3: To really help us grow, because ideally what we want is an entity or group that will help us make very repeatable, simple, repeatable investments.

Speaker #3: With very low friction, and have the relationships with the health systems we need to continue to kind of grow the portfolio. And so that's where we are.

Speaker #3: We've been meeting people. I mean, obviously, we've had a lot to do just in the existing portfolio. But as we look forward, a big priority for me is to kind of start to narrow down the kind of field of options for us in terms of how we might do this.

Zachary Vaughan: As we look forward, you know, big priority for me is to kind of start to narrow down the kind of field of options for us in terms of how we might do this.

Zachary Vaughan: As we look forward, you know, big priority for me is to kind of start to narrow down the kind of field of options for us in terms of how we might do this.

Speaker #10: Got it. Sorry. Okay. That's good color. And then just lastly, on the new development, I think it was $112 million, which market was that in?

Alyssa Barry: Got it. Sorry. Okay, that's good color. Then just lastly, on the new development, the, I think it was CAD 112 million, which market was that in, and what's the, what sort of yield expectations are you targeting?

Pammi Bir: Got it. Sorry. Okay, that's good color. Then just lastly, on the new development, the, I think it was CAD 112 million, which market was that in, and what's the, what sort of yield expectations are you targeting?

Speaker #10: And what's the sort of yield expectations are you targeting?

Zachary Vaughan: It's in Ontario. That's about what we can say at the moment, although we'll be able to, there'll be more news on it. Look, I think when we're all said and done, the starting yield will be kind of 7%-ish.

Speaker #3: It's in Ontario. That's about what we can say at the moment. Although we'll be able to they'll be more news on it. But look, I think when we're all said and done, the starting yield will be kind of 7 percent-ish.

Zachary Vaughan: It's in Ontario. That's about what we can say at the moment, although we'll be able to, there'll be more news on it. Look, I think when we're all said and done, the starting yield will be kind of 7%-ish.

Alyssa Barry: Okay.

Pammi Bir: Okay.

Zachary Vaughan: Which, again, as we look at it, and you say, if you can generate that with a very long-term commitment, that's essentially supported by the government...

Zachary Vaughan: Which, again, as we look at it, and you say, if you can generate that with a very long-term commitment, that's essentially supported by the government...

Speaker #3: Which, again, as we look at it—and you say if you can generate that with a very long-term commitment—that's essentially supported by the government.

Alyssa Barry: Right

Pammi Bir: Right

Speaker #3: On an infrastructure-like asset with ongoing it's pretty compelling in my mind where I think there's infrastructure capital that would look for leverage 7s all in.

Zachary Vaughan: ... on an infrastructure like asset with, you know, ongoing rent, like, it's pretty compelling in my mind, where, you know, I think there's infrastructure capital that would look for leveraged 7s all in.

Zachary Vaughan: ... on an infrastructure like asset with, you know, ongoing rent, like, it's pretty compelling in my mind, where, you know, I think there's infrastructure capital that would look for leveraged 7s all in.

Speaker #3: And so we feel quite good about—again, we're not developers for profit—but if you were to look at, I think, what the development profit on these could be, it could be quite meaningful.

Alyssa Barry: Right.

Pammi Bir: Right.

Zachary Vaughan: We feel quite good about. Again, we're not developers for profit. You know, if you were to look at, I think, what the development profit on these could be, it could be quite meaningful, although that's not our intent. Our intent is to build these and kind of hold them.

Zachary Vaughan: We feel quite good about. Again, we're not developers for profit. You know, if you were to look at, I think, what the development profit on these could be, it could be quite meaningful, although that's not our intent. Our intent is to build these and kind of hold them.

Speaker #3: Although that's not our intent or our intent is to build these and kind of hold them.

Speaker #10: Sorry, the 7% is going in. I just want to clarify—7% going in, plus the steps. Yeah, annual escalators in those leases? Yeah, okay.

Alyssa Barry: Sorry, the 7% is going in. Just want to clarify, 7% going in-

Pammi Bir: Sorry, the 7% is going in. Just want to clarify, 7% going in-

Zachary Vaughan: Correct. Correct.

Zachary Vaughan: Correct. Correct.

Alyssa Barry: plus the steps, yeah, like annual escalators.

Pammi Bir: plus the steps, yeah, like annual escalators.

Zachary Vaughan: Correct.

Zachary Vaughan: Correct.

Alyssa Barry: on those leases. Yeah. Okay.

Pammi Bir: on those leases. Yeah. Okay.

Speaker #3: Yeah. Correct. And these are very long-term commitments, right? So this is not like, "Hey, it's a 10-year lease on a warehouse and we're going to battle it out." We're either going to win or lose depending on if someone else builds some these are very long-term commitments.

Zachary Vaughan: Yeah, correct.

Zachary Vaughan: Yeah, correct.

Alyssa Barry: Yeah.

Pammi Bir: Yeah.

Zachary Vaughan: Over, and these are very long-term commitments, right?

Zachary Vaughan: Over, and these are very long-term commitments, right?

Alyssa Barry: Right.

Pammi Bir: Right.

Zachary Vaughan: This is not like, hey, it's a 10-year lease on a warehouse, and, you know, we're gonna battle it out. We're either gonna win or lose, depending on if someone else builds some. Like, these are very long-term commitments, and they are infrastructure-like, and we saw that with Lakeridge. I mean, this one's 2x the size.

Zachary Vaughan: This is not like, hey, it's a 10-year lease on a warehouse, and, you know, we're gonna battle it out. We're either gonna win or lose, depending on if someone else builds some. Like, these are very long-term commitments, and they are infrastructure-like, and we saw that with Lakeridge. I mean, this one's 2x the size.

Speaker #3: And they are infrastructure-like. And we saw that with Lakeridge. And, I mean, this one's twice the size.

Speaker #10: Right. Lastly, just want to confirm the European asset sale. Is that roughly, just doing the math based on your disclosure, roughly in the 6.5% range?

Alyssa Barry: Right. Lastly, just to want to confirm the, this, the European asset sale, is that roughly in the, just doing the math, based on your disclosure, roughly in the 6.5% range in terms of the cap rate?

Pammi Bir: Right. Lastly, just to want to confirm the, this, the European asset sale, is that roughly in the, just doing the math, based on your disclosure, roughly in the 6.5% range in terms of the cap rate?

Speaker #10: In terms of the cap rate.

Speaker #11: Yeah. That's pretty close.

Stephanie Karamarkovic: Yeah, that's pretty close.

Stephanie Karamarkovic: Yeah, that's pretty close.

Speaker #10: Yeah. Okay. Thanks very much. I'll turn it back.

Alyssa Barry: Yep. Okay. Thanks very much. I'll turn it back.

Pammi Bir: Yep. Okay. Thanks very much. I'll turn it back.

Speaker #3: Thanks.

Zachary Vaughan: Thanks.

Zachary Vaughan: Thanks.

Speaker #11: We have a follow-up question from Juliana Thornhill with National Bank. Please go ahead.

Operator: We have a follow-up question from Julian Hawthorne with National Bank. Please go ahead.

Operator: We have a follow-up question from Julian Hawthorne with National Bank. Please go ahead.

Speaker #12: Hey, guys. I'll just be brief. I was just wondering, was there an option to sell the management rights to TPG or possibly another buyer?

Giuliano Taddeo: Hey, guys. I'll just be brief. I was just wondering, was there an option to sell the management rights to TPG or possibly another buyer? What, yeah, was that considered at all?

Giuliano Thornhill: Hey, guys. I'll just be brief. I was just wondering, was there an option to sell the management rights to TPG or possibly another buyer? What, yeah, was that considered at all?

Speaker #12: And yeah, was that considered at all?

Speaker #3: Yeah. Do you mean the management in terms of our joint venture?

Zachary Vaughan: Yeah. Do you mean the management in terms-

Zachary Vaughan: Yeah. Do you mean the management in terms-

Giuliano Taddeo: Yeah

Giuliano Thornhill: Yeah

Zachary Vaughan: - of our joint venture?

Zachary Vaughan: - of our joint venture?

Speaker #12: Yeah. Exactly. Exactly.

Giuliano Taddeo: Yeah.

Giuliano Thornhill: Yeah.

Zachary Vaughan: Or-

Zachary Vaughan: Or-

Giuliano Taddeo: Exactly the.

Giuliano Thornhill: Exactly the.

Zachary Vaughan: No.

Zachary Vaughan: No.

Speaker #3: No. Yeah. No. I mean, look, we're not look, it's not something we would unlike Vital, this is a very important partnership for us. And we both enter this thing investing both of our own capital.

Giuliano Taddeo: industry and.

Giuliano Thornhill: industry and.

Zachary Vaughan: Yeah. No, that's not. I mean, look, we're not. Look, I don't. It's not something we would, unlike Vital, you know, this is a very important partnership for us. You know, we both enter this thing investing both of our own capital. It's not, and it's not something we thought about now. I think we more thought about the management of kind of the outpatient assets that just require in that market. We don't quite have the scale, so you either have to triple the size of the portfolio or exit. No, we still have our venture. It's still intact, although we sold a few assets out of it.

Zachary Vaughan: Yeah. No, that's not. I mean, look, we're not. Look, I don't. It's not something we would, unlike Vital, you know, this is a very important partnership for us. You know, we both enter this thing investing both of our own capital. It's not, and it's not something we thought about now. I think we more thought about the management of kind of the outpatient assets that just require in that market. We don't quite have the scale, so you either have to triple the size of the portfolio or exit. No, we still have our venture. It's still intact, although we sold a few assets out of it.

Speaker #3: It's not and it's not something we thought about now. I think we more thought about the management of kind of the outpatient assets that just require in that market.

Speaker #3: We don't quite have the scale so you either have to triple the size of the portfolio or exit. But no, we still have our venture.

Speaker #3: It's still intact, although we sold a few assets out of it.

Speaker #12: Right. And then when does the board or has the board established a framework for kind of getting to distribution increases? Like a certain payout question I had was just, what does net debt deal look like adjusted for the year for the transaction activity?

Giuliano Taddeo: When does the board, has the board established a framework for kind of getting to distribution increases, like a certain payout level? The final question I had was just, what does net debt to EBITDA look like, adjusted for the year, for the transaction activity?

Giuliano Thornhill: When does the board, has the board established a framework for kind of getting to distribution increases, like a certain payout level? The final question I had was just, what does net debt to EBITDA look like, adjusted for the year, for the transaction activity?

Stephanie Karamarkovic: Yeah, maybe first starting with distribution policy. I think, you know, the board hasn't broached that yet. I think we're still in, you know, a bit of transition mode in terms of the disposition activity and growth. Really, we're looking at 2026 as a year to kind of reposition the portfolio and start growing again. I think, you know, things during the year might be slightly noisy in terms of earnings, just as we try to fund match as best as possible our proceeds and redeployment or debt repayment. Yeah, looking towards the end of 2027 or 2026, sorry, we'll feel in a much more kind of stable position and be able to assess at that point.

Speaker #11: So yeah, maybe for starting with distribution policy. I think the board hasn't broached that yet. I think we're still in a bit of transition mode in terms of the disposition activity and growth.

Stephanie Karamarkovic: Yeah, maybe first starting with distribution policy. I think, you know, the board hasn't broached that yet. I think we're still in, you know, a bit of transition mode in terms of the disposition activity and growth. Really, we're looking at 2026 as a year to kind of reposition the portfolio and start growing again. I think, you know, things during the year might be slightly noisy in terms of earnings, just as we try to fund match as best as possible our proceeds and redeployment or debt repayment. Yeah, looking towards the end of 2027 or 2026, sorry, we'll feel in a much more kind of stable position and be able to assess at that point.

Speaker #11: And so really, we're looking at 2026 as a year to kind of reposition the portfolio and start growing again. And so I think things during the year might be slightly noisy in terms of earnings just as we try to fund match as best as possible our proceeds and redeployment or debt repayment.

Speaker #11: But yeah, looking towards the end of '27 or '26, sorry, we'll feel in a much more kind of stable position and be able to assess at that point.

Stephanie Karamarkovic: With respect to debt to EBITDA, the 8.7%, or 8.7x I quoted, adjusting for Vital. That's a good indicator of where things trend in the next couple of quarters. With the further deleveraging from the European asset sale, we could see that come down a little bit, we're in that low or high 8s range for the next little bit.

Speaker #11: With respect to debt to EBITDA, so the 8.7% or 8.7 times that I quoted—that's adjusting for Vital. I think that that's probably a good indicator of where things trend in the next couple of quarters.

Stephanie Karamarkovic: With respect to debt to EBITDA, the 8.7%, or 8.7x I quoted, adjusting for Vital. That's a good indicator of where things trend in the next couple of quarters. With the further deleveraging from the European asset sale, we could see that come down a little bit, we're in that low or high 8s range for the next little bit.

Speaker #11: With the further deleveraging from the European asset sale, we could see that come down a little bit. But I think we're kind of in that low or high 8s range for the next little bit.

Speaker #12: Okay. Thank you, guys. Thanks, Julian.

Giuliano Taddeo: Okay. Thank you, guys.

Giuliano Thornhill: Okay. Thank you, guys.

Stephanie Karamarkovic: Thanks, Julian.

Stephanie Karamarkovic: Thanks, Julian.

Zachary Vaughan: Thanks, Julian.

Zachary Vaughan: Thanks, Julian.

Speaker #11: The next question is from Dean Wilkinson with CIBC. Please go ahead.

Operator: The next question is from Dean Wilkinson with CIBC. Please go ahead.

Operator: The next question is from Dean Wilkinson with CIBC. Please go ahead.

[Company Representative] (Chorus Call): Thanks. Morning, everyone. Most everything has been asked already. I just want to confirm on the Healthscope, so pro forma the asset sales, I get that at around 11% with or 8% from the sort of 6 6. Would that be in the ballpark range, Stephanie?

Speaker #13: Thanks. Morning, everyone. Most everything has been asked already. I just want to confirm, on the health scope, so pro forma the asset sales, I get that at around 11% or 8% from the sort of 6.6.

Dean Wilkinson: Thanks. Morning, everyone. Most everything has been asked already. I just want to confirm on the Healthscope, so pro forma the asset sales, I get that at around 11% with or 8% from the sort of 6 6. Would that be in the ballpark range, Stephanie?

Speaker #13: Would that be in the ballpark range? Stephanie?

Speaker #11: Yeah. I think that sounds right. I can confirm that offline. And if it's not, I'll let you know. But I think that sounds right.

Stephanie Karamarkovic: Yeah, I think that sounds right. I can confirm that offline, and if it's not, I'll let you know, but I think that sounds right.

Stephanie Karamarkovic: Yeah, I think that sounds right. I can confirm that offline, and if it's not, I'll let you know, but I think that sounds right.

Speaker #13: Okay. Sounds good. And then just your comments about sort of earnings neutral on the dispositions and the rest of that. Could we then infer sort of that 11, 12 cent per share quarterly run rate on FFO as a pretty decent number?

[Company Representative] (Chorus Call): Okay, sounds good. Just, you know, your comments about sort of earnings neutral on the dispositions and the rest of that. Could we then infer sort of that CAD 0.11, 0.12 per share quarterly run rate on FFO was a pretty decent number?

Dean Wilkinson: Okay, sounds good. Just, you know, your comments about sort of earnings neutral on the dispositions and the rest of that. Could we then infer sort of that CAD 0.11, 0.12 per share quarterly run rate on FFO was a pretty decent number?

Speaker #11: Yeah. I don't want to give concrete guidance. But yeah, I think 2026 we see as kind of a flat year overall to 2025 just given all the repositioning activities.

Stephanie Karamarkovic: Yeah, I don't want to give, you know, concrete guidance, but yeah, I think 2026 we see as kind of a flat year overall to 2025, just given all the repositioning activities.

Stephanie Karamarkovic: Yeah, I don't want to give, you know, concrete guidance, but yeah, I think 2026 we see as kind of a flat year overall to 2025, just given all the repositioning activities.

Speaker #13: Right. That makes sense. That's it. Thanks.

[Company Representative] (Chorus Call): Right, that makes sense. That's it. Thanks.

Dean Wilkinson: Right, that makes sense. That's it. Thanks.

Speaker #12: Thanks, Dean.

Zachary Vaughan: Thanks, team.

Zachary Vaughan: Thanks, team.

Speaker #11: This concludes the question-and-answer session. I'd like to turn the conference back over to Alyssa Barry for any closing remarks.

Operator: This concludes the question and answer session. I'd like to turn the conference back over to Alyssa Barry for any closing remarks.

Operator: This concludes the question and answer session. I'd like to turn the conference back over to Alyssa Barry for any closing remarks.

Speaker #1: Thank you, everyone, for joining us today. We appreciate your support. We look forward to updating you on our progress next quarter. For any further questions, please feel free to reach out to us directly.

Alyssa Barry: Thank you, everyone, for joining us today. We appreciate your support. We look forward to updating you on our progress next quarter. For any further questions, please feel free to reach out to us directly. With that, have a great rest of your day.

Alyssa Barry: Thank you, everyone, for joining us today. We appreciate your support. We look forward to updating you on our progress next quarter. For any further questions, please feel free to reach out to us directly. With that, have a great rest of your day.

Speaker #1: And with that, have a great rest of your day.

Operator: This brings to a close today's conference call. You may disconnect your lines. Thank you for participating, and have a pleasant day.

Operator: This brings to a close today's conference call. You may disconnect your lines. Thank you for participating, and have a pleasant day.

Q4 2025 Northwest Healthcare Properties REIT Earnings Call

Demo

Northwest Healthcare Properties

Earnings

Q4 2025 Northwest Healthcare Properties REIT Earnings Call

NWH_u.TO

Wednesday, February 25th, 2026 at 3:00 PM

Transcript

No Transcript Available

No transcript data is available for this event yet. Transcripts typically become available shortly after an earnings call ends.

Want AI-powered analysis? Try AllMind AI →